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Abstract: Chitosan is one of the most studied natural origin polymers for biomedical applications.
This review focuses on the potential of chitosan in localized antimicrobial therapy to address the
challenges of current rising antimicrobial resistance. Due to its mucoadhesiveness, chitosan offers
the opportunity to prolong the formulation residence time at mucosal sites; its wound healing
properties open possibilities to utilize chitosan as wound dressings with multitargeted activities
and more. We provide an unbiased overview of the state-of-the-art chitosan-based delivery systems
categorized by the administration site, addressing the site-related challenges and evaluating the
representative formulations. Specifically, we offer an in-depth analysis of the current challenges of
the chitosan-based novel delivery systems for skin and vaginal infections, including its formulations
optimizations and limitations. A brief overview of chitosan’s potential in treating ocular, buccal and
dental, and nasal infections is included. We close the review with remarks on toxicity issues and
remaining challenges and perspectives.
Keywords: chitosan; antimicrobial activity; topical infections; antimicrobial resistance; drug delivery
systems; scaffolds; skin infections; vaginal infections
1. Introduction
The Organization for Economic Co-operation and Development has recently predicted
that 2.4 million people in Europe, North America, and Australia will die from infections
with resistant microorganisms in the next 30 years [1]. World Health Organization (WHO)
considers increased antibiotic resistance the most significant challenge to human health [2].
In an era of increased incidence of resistant microorganisms (antimicrobial resistance,
AMR) and alarming reports of confirmed resistance to most prescribed antibiotics [3], it
is of tremendous importance to look at all available resources to combat this threat. Yet,
surprisingly unsuccessful pipelines of antimicrobial candidates [4] indicate that our search
might not be well-enough targeted to lead to fast and viable improvements.
Although a single approach cannot address such a complex and multi-causative threat,
we propose that more attention be given to utilizing nature as a source of the safe and effi-
cient antimicrobial arsenal. Despite the great potential of marine resources as biodegradable
biomaterials and an increasing number of marine organism-based biomaterials reaching
the market, the full potential of these resources is yet to be realized [5]. Among various
natural antimicrobials, we aimed to highlight the pharmaceutical excipient that has not
reached its full potential as antimicrobial, namely chitosan.
Chitosan originates from chitin, the second most abundant polysaccharide extracted
from the shells of crustaceans and cytoderm of fungi and green algae [6]. It has been
proven to exhibit potent antimicrobial activities [7], and it can act in synergy to enhance
the antimicrobial potential of other antimicrobials [8]. However, it has also been shown
that the formulation features are critical for achieving the maximum effect of any antimi-
crobial [2] and thus need to be tailored when utilizing chitosan’s antimicrobial potential [8].
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Moreover, its formulations in the nanosized range were reported to restrain the resistance
development in bacteria [9].
1.1. Localized Therapy
Localized drug therapy offers numerous advantages such as:
• Achieving a high drug concentration at the infection site,
• Limiting systemic drug exposure often responsible for faster development of AMR,
• Consequently, reducing the systemic side effects,
• Improving the safety drug profile in, for example, pregnant patients [10].
1.2. Structure of Review
In the review, we offer a novel focus on the role of chitosan as an intrinsic antimicrobial.
When facing the limited antimicrobial therapy options accompanied by a scarcity of novel
antimicrobials, it is imperative to extend the arsenal of antimicrobial resources beyond
current pipelines. Therefore, here we highlight the challenges of AMR and consider the
advantages of efficient localized drug therapy. We focus on the extended role of chitosan
as an excipient with intrinsic antimicrobial properties, which remain to be fully explored.
We address the infection site’s challenges and the corresponding challenges the chitosan
formulation should overcome to optimize the treatment. We also provide an extensive
overview of representative literature, emphasizing the main antimicrobial findings and
the delivery systems summary based on the type of targeted microorganisms. The in-
depth review highlights the role of chitosan in skin and vaginal infections, with a brief
overview of the role of chitosan in ocular, buccal and dental, and nasal sites. We finalize the
review by addressing the toxicity, limitations, sustainability, and perspectives of chitosan’s
antimicrobial use.
2. Polymers’ Role in Antimicrobial Therapy
2.1. Polymers Used in Localized Antimicrobial Therapy
As an alternative to traditional antibiotics, more emphasis could be placed on natural
resources for drug delivery strategies [2]. Since around half of the earth’s biodiversity
is found in the oceans, polymers from marine sources are particularly interesting in that
respect [11,12].
Both natural and synthetic polymers are frequently used as excipients in biomedical
applications intended for antimicrobial therapy. In recent years, the attraction towards
natural polymers has grown due to the distinct properties and the abundance of these
compounds in nature. Among the natural polymers with an inherent antimicrobial activity,
chitosan appears as one of the most promising [13,14]. The synthetic polymers could also
bear antimicrobial properties or could be modified to exhibit such properties. Antimicrobial
polymers bearing quaternary ammonium or phosphonium as functional groups are the
most widely studied among the polymers with antimicrobial properties [14,15]. The
most frequently used synthetic polymers for localized therapy are poly(caprolactone)
(PCL), poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), and poly(vinyl alcohol)
(PVA) [16]. Furthermore, these polymers are also used alone or in combination with other
natural and synthetic polymers to improve the treatment outcomes or physical properties.
2.2. Chitosan’s Antimicrobial Properties and Its Role in Localized Antimicrobial Therapy
Chitosan is a natural polycationic linear polysaccharide composed of (1→4)-2-amino-2-
deoxy-β-D-glucan and (1→4)-2-acetamido-2-deoxy-β-D-glucan obtained from deacetylated
chitin [17–19]. Chitin is the second most abundant natural polysaccharide, whereas chitosan
is the most investigated marine polysaccharide [11,17]. Chitin is not only commonly
found in marine sources but also in fungi; however, its content there is lower than in
crustaceans [20]. Nevertheless, with correct cultivation, fungi could be a realistic alternative
source to the crustaceans for biomaterials and biomedical applications [21].
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In addition to the intrinsic antimicrobial [22–25] and antifungal [26–28] activity of chi-
tosan, this polymer exhibits anti-inflammatory activity [29–31], antioxidative effects [32,33],
hemostatic activity [34,35], and healing properties [36–38]. Importantly, chitosan is both
biocompatible [39,40] and biodegradable [41] and is approved by the U.S. Food and Drug
Administration for certain applications [42]. These properties make chitosan an attrac-
tive building block in drug delivery systems and scaffolding. Furthermore, its muco and
bioadhesive properties [43,44] increase its applicability in topical, local applications and
formulations intended for skin and mucosal membranes. These properties are valuable
attributes in materials intended to treat mucosa surfaces and infected, inflamed, and dam-
aged skin. However, the biological activity of chitosan is dependent on the degree of
deacetylation (DDA) and molecular weight (MW) [45]. Due to the deacetylation of the
poorly soluble chitin, pH affects the activity and solubility of chitosan. The polycationic
nature of chitosan is the basis for most of its biological activities [17]. In addition to effects
of deacetylation, the chitosan’s functional groups, the amino- and hydroxyl- groups, are
used as sites for polymer modifications to improve its physical and biological features [46].
The mechanisms behind the antimicrobial activity of chitosan are not clear; however,
the four most prominent known mechanisms are: (i) electrostatic interactions with microbial
membranes and disruption of the membrane, (ii) complexation with microbial DNA,
(iii) accumulation and enveloping on the microbial membrane, and (iv) chelation of divalent
cations [18,19].
Bacterial membranes are slightly negatively charged in Gram-negative bacteria mainly
because of lipopolysaccharides in the outer membrane and in Gram-positive bacteria due
to lipoteichoic acids [47]. Due to its polycationic nature, chitosan can interact with the
bacterial membrane [19]. This interaction causes destabilization and changes the membrane
permeability, leading to the lysis of the bacteria [48–50].
The second mechanism is a complexation between chitosan and DNA mainly linked
to the chitosan of lower MW. Because of the complexation between chitosan and DNA,
the bacterial protein synthesis is hampered [19], resulting in death in both bacteria and
fungi [51,52].
Chitosan, especially of higher MW, can deposit on the bacterial membrane (due to the
nature of the membrane) and create an envelope on the surface of the bacteria, disrupting
the bacteria’s uptake of nutrients and waste removal, leading to bacterial death [18,53].
The fourth mechanism is based on chitosan’s ability to chelate divalent cations [54].
Bacteria utilize these divalent cations to stabilize the membrane; therefore, chitosan desta-
bilises the bacterial membrane [18].
The antimicrobial mechanisms of chitosan against fungi and viruses are even less
studied than those against bacteria. However, the antifungal activity is believed to originate
from the interaction between chitosan and the negatively charged fungal membrane caused
by the presence of negatively charged sialic acids [19,55]. The antiviral activity of chitosan
might also originate in the electrostatic interactions with chitosan and subsequent direct
eradication. It is also proposed that the activity might result from chitosan’s ability to block
viruses from interacting with the cell surface or by boosting immune response [56].
3. Chitosan-Based Drug Delivery Systems for Localized Antimicrobial Therapy
3.1. Particles and Carriers
Chitosan-based microparticles (MPs) and nanoparticles (NPs), or carriers, have at-
tracted attention as drug delivery systems in infection control and prevention due to their
unique characteristics [57,58]. Generally, polymeric particles could protect the active com-
pound from degradation, provide controlled release of the antimicrobial compound into
the intended tissue, enhance penetration or permeation, increase the concentration at the
intended site and intracellularly, and reduce adverse effects and systemic exposure [57–60].
Chitosan-based MPs and NPs are utilized in microbial eradication as carriers of antimicro-
bial compounds because of their inherent antimicrobial activity resulting from the high
density of positively charged amino groups and the surface-to-volume ratio [60,61]. Fur-
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thermore, chitosan particles are considered safe to mammalian cells, able to modulate the
immune system, and possess excellent permeability enhancing properties [62]. Chitosan
particles alone [63], as well as several aspects of their antimicrobial activity, have been
assessed, including acting as carriers of other antimicrobial compounds [64,65] and being
embedded in a secondary system [66], all intended for localized, antimicrobial therapy.
3.2. Coating Material and Excipients
Chitosan offers versatile ways of application in pharmaceutical formulations. As coat-
ing material or excipient in drug delivery systems, chitosan can introduce beneficial quali-
ties that tailor the system for topical application and optimize antimicrobial activity [67].
The addition of chitosan to a formulation intended for localized therapy can improve appli-
cability by providing bioadhesiveness and sustained release to the system [68]. Moreover,
the antimicrobial activity might be altered due to the intrinsic characteristics of chitosan or
the synergy of polymer and active ingredients [69]. A variety of these strategies have been
studied; chitosan-coating of MPs and NPs, chitosan-functionalized systems, encapsulated
chitosan, hybrid systems including chitosan, and surface modification of drug delivery sys-
tems [8,22,70–72]. Moreover, the preparation method can tailor the properties of chitosan
to improve the suitability of formulation for the specific routes of application [8,73].
3.3. Polymer-Based Gels
Chitosan-based hydrogels can be applied as therapeutic drugs vehicles or active in-
gredients, secondary vehicles for MPs and NPs containing drugs or active ingredients, and
as intrinsic antimicrobials [67,74]. The use of chitosan-based hydrogels in pharmaceutical
applications is widely studied, especially targeting improved wound healing and therapy
of localized infections [75,76]. Numerous favourable properties of chitosan-based gels,
such as biocompatibility, biodegradability, bioadhesiveness, antimicrobial activity, as well
as the ability to disrupt biofilms, make them highly attractive for biomedical applica-
tions [74,77]. Moreover, chitosan-based hydrogels provide sustained and controlled drug
delivery through various environmental stimuli, such as thermosensitive or pH-sensitive
gels [67].
3.4. Scaffolds
There are several requirements involved in scaffolds intended for localized infections,
and the specific requirements depend on the site of the infection and the condition of
the infected area. Scaffolds must be biocompatible, biodegradable, maintain moisture
balance, allow oxygen exchange, protect from the surrounding environment, and permit
cell migration and tissue regeneration [78]. Scaffolds involving chitosan have shown
the ability to maintain moisture balance [79], allow oxygen exchange [80], protect from
the environment [81], allow cell migration [81], and promote factors important for tissue
regeneration [82]. Among the scaffolds, sponges, films, fibres, and matrices are widely
used [78].
Chitosan-based delivery systems for the localized therapy of infections are summa-
rized in Figure 1.
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4. Role of Chitosan in Localized Therapy of Skin Infections
4.1. Common Skin Infections and Microorganisms
The skin is the larg st org of the human body and is constantly in contact with its
surround s [83], serving as the body’s first defenc line [84]. The skin is continuously
challenged by esse tial, opportunistic, and patho e c microorganisms that could cause
infections if the skin barrier is b eached or otherwise compromised [85,86]. Even with
an ffective protective barrier, infections are r latively freque t, becoming a growing
concern [87]. The burd n of skin infections vers a wide variety of conditions often
classified as skin and oft tissue infections (SSTIs). Uncomplicated SSTIs are typically
comprised of impetig , ecthyma, erysipelas, n folliculitis, while complicated SSTIs
include more eve e, a ute wound infections, chronic wound infections, cellulitis, and
necrotizing skin infections [88]. U.S. Food and Drug Administration d fines the latter as
acute bacterial ski and skin structure infections [89]. Additionally, chronic wounds are
considered a massive burden on the health care systems [90], with Staphylococcus aureus,
Pseudomonas aeruginosa, and Escherichia coli among the bacteria most frequently found in
these skin infections [91]. Wounds and other skin infections are also polymicrobial in
nature, therefore, they are more complex and harder to treat [92].
Superficial fungal infections are an increasing problem affecting between 20–25% of
the global population [93,94]. A fungus of importance is Candida albicans, an opportunistic
fungus and a natural part of the human microbiota frequently found in microbial communi-
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ties in chronic wounds [95,96]. Resistance among fungal species is growing, and relatively
few treatment options are available [97].
Furthermore, there are many viral infections such as varicella-zoster, herpes zoster,
molluscum contagiosum virus, and human herpesvirus 6. However, these infections are
often self-limiting and do not require treatment [98]. Herpes simplex virus infections, such
as herpes labialis, could be treated locally if the outbreak of the infection is localized in a
limited area [99,100]. However, localized, antiviral skin therapy utilizing chitosan delivery
systems is underrepresented compared to antibacterial and antifungal treatment.
The burden of infected nonhealing or hard-to-heal wounds, along with other skin
diseases, is rapidly increasing, creating a strain on medical services [101]. The term chronic
wounds covers a wide variety of conditions, with diabetic foot ulcers, venous leg ulcers,
and pressure ulcers being the most relevant [102]. The majority of these wounds are halted
in the inflammatory phase, which delays the proliferation and epithelization and deceler-
ates the healing process [103]. Chronic wounds usually are polymicrobial in nature, with
bacteria linked to the genetics of each patient [104]. However, S. aureus and P. aeruginosa are
recognized as strong contributors to chronicity in nonhealing wounds [105]. Wolcott et al.
analyzed bacteria found in chronic wounds of 2963 patients, and S. aureus, Staphylococcus
epidermidis, Finegoldia magna, and P. aeruginosa were the most frequently found in these
wounds [106]. Yet, the presence of certain microorganisms in the wound bed does not di-
rectly indicate an infection [107]. S. aureus and P. aeruginosa are the most common bacteria to
produce biofilm networks in the wound bed [103,108], and these biofilms are communities
of bacteria living together in extracellular polymeric substances which provide protection
and facilitate adhesion to the affected tissue [109]. In addition to the increased protection of
microorganisms in biofilms, the matrix allows improved communication between bacteria
and increases resistance by allowing bacteria to remain in a dormant state for prolonged
periods [103,107]. These biofilm matrices are found in approximately 60–80% of all human
infections [110], and bacteria in biofilms are often 1000-fold more resistant than planktonic
bacteria, further increasing the challenge in eradicating these pathogens [111]. Fungi are
also often a part of the polymicrobial community in chronic wounds, and Candida spp. are
regularly reported as the most recurrent fungi [95]. Wounds or other skin breaches could
potentially cause other forms of SSTIs if left untreated [112]. Utilizing topical antibiotics in
the treatment of chronic wounds is not uncommon; however, the evidence behind their
use is somewhat limited [113]. The selection of the type of antibiotic is dependent on the
microbial picture [105,110].
4.2. Challenges of Antimicrobial Treatment and Delivery to the Skin
The skin represents an attractive route in the therapy of localized microbial infections,
mainly due to the potential of higher local drug concentrations [114]. Additionally, the
demand for therapeutic options for skin infection is increasing with growing numbers of
SSTIs globally [115]. However, several limitations are linked to the skin as a target site for
delivering antimicrobial compounds.
The skin structure comprises three main layers; epidermis, dermis, and hypoder-
mis [83]. The epidermis mainly consists of keratinocytes and is where the binding of
pharmaceutical compounds, metabolism, and active transport occurs [116]. Below the
epidermis is a layer of connective tissue composed of fibroblasts, namely the dermis,
responsible for the structure and elasticity of the skin [117]. The hypodermis, or the subcu-
taneous tissue, is the innermost layer of the skin and consists of connective tissue, however,
looser than the connective tissue in the dermis. The main functions of the hypodermis
are protection from physical impact, temperature regulation, and energy storage [117].
The uppermost and primary protective layer, the stratum corneum (SC), plays a key role
in dermal delivery [118]. The SC limits the penetration of active compounds due to the
lipophilic nature of the barrier, which prevents absorption of molecules with an MW of
more than 500 Da [118–120]. The SC is structured in a distinct way, often referred to as the
brick-and-mortar model, where the corneocytes represent the bricks and the lipid matrix
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represents the mortar [83]. In the localized treatment of dermal infections, the aim is to
assure penetration into the infection site while avoiding the potential absorption. The
penetration of the active compound might be slow, creating challenges in reaching the
desired concentration [121]. Determining the concentration of the compound within the
skin layers, as well as determining the compound clearance and degradation from these
layers, is challenging as well as [122].
In localized skin infections, the heterogeneity between patients might pose another
challenge. The skin condition might be altered if the patient suffers from SSTIs and skin
impairments in general. In the case of wounds or impaired skin, the skin’s barrier function
might be lost, and penetration or permeation through the skin might increase [83]. This
might lead to lowered concentrations of the antimicrobial compounds in the intended site
and could increase the potential of systemic side effects. Furthermore, the skin or wound
environment might be altered, and the skin barrier weakened because of, and depending
on, the given condition, e.g., infection, wounds, lesions, or inflammation, or thickened, due
to ichthyosis or cancer. In these cases, the absorption into or through the skin is different
from normal or healthy skin [123]. Additionally, impairment of the skin, especially if the
damage reaches into the deeper skin layers or is bleeding, could cause alteration to the
pH on the surface from the naturally more acidic milieu on the SC. This more neutral
environment is beneficial for the growth of many pathogenic microorganisms, further
increasing the challenge in treating the SSTIs [124]. Impaired skin, especially wounds and
lesions, could contain high volumes of exudate, essential for maintaining a proper healing
cascade and maintaining a moist wound bed. However, extensive volumes of exudate
could lead to further reduced healing [125,126] and introduce challenges in maintaining
contact between therapeutic formulation and the infection site, leading to lower retention or
residence time of the therapeutic in the affected area [107]. These and other factors, such as
low permeation or degradation, could result in the need for frequent drug administration
onto a damaged and painful area [127] and further impaired healing [127]. In addition,
the potential of local side effects or skin irritation needs to be accounted for [114]. Allergic
contact dermatitis is not uncommon [118]. Occlusion effects could also potentially increase
pH and temperature at the treatment site and cause skin irritation; however, these effects
are often easy to avoid [118].
The most significant challenges in antimicrobial skin therapy are the numerous vari-
ations in conditions and the microbial diversity between patients and within the same
SSTI [83,113]. The microbial picture depends on the patients’ genetics and the environment
and varies between different sites on the human body [104,128]. Furthermore, biofilms can
be found in up to 80% of all infections [110]. The AMR results from different mechanisms,
such as restricted penetration of antimicrobial compounds into the biofilm matrix, altered
metabolic activity in the microorganisms, altered gene expression, and microorganisms
that remain in a dormant state. Topical therapy might increase the local concentration of
antimicrobial compounds, such as mupirocin, metronidazole, and silver sulfadiazine [129].
Moreover, the biofilms are often firmly adhering to skin structures and might stretch further
into the deeper skin layers, rendering removal challenging [107,125].
4.3. Tackling the Challenges of Infected Skin—The Delivery Strategies, Systems, and Scaffolds
In SSTIs and wound healing, chitosan is utilized to produce various drug delivery
systems and scaffolds for wound healing and tissue regeneration. The range of these
systems and scaffolds varies between polymer-based gels, nanofibrous scaffolds, and
particles for regeneration, antimicrobial activity, and carrying the antimicrobial compounds.
However, most systems and scaffolds are intended to heal wounds [78].
The scaffold should protect the wound from external contamination, maintain mois-
ture, allow gas exchange, prevent bacterial growth, or eradicate bacteria in the wound
bed, facilitate all stages of the wound healing cascade, and it should be biodegradable and
biocompatible [62,78,130]. Chitosan possesses many of these necessary properties [16,19].
Additionally, it can assist in a sustained and controlled release of pharmaceutical com-
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pounds, such as antimicrobials, both in micro and nanotechnology [130–132]. Its retention
in the skin could be improved while maintaining the balance between retention and
penetration to ensure sufficient concentrations of the pharmaceutical compound [133].
Furthermore, advanced scaffolds could mimic the extracellular matrix to further promote
skin healing [130].
These delivery systems could be classified according to composition and size range. In
skin repair and wound healing, these could be classified as NPs, nanocomposites, coatings,
and scaffolds, depending on their intended use and attribution in the therapy [62]. As a
bioactive polymer, chitosan is easily developed for gels, membranes, nanofibers, MPs, NPs,
sponges, and scaffolds [134]. Chitosan-based delivery systems targeting skin infections are
summarized in Figure 2.




Figure 2. Summary of chitosan-based drug delivery systems and scaffolds intended for skin admin-
istration with their respective targeted microorganisms and examples of skin infections. The illus-
tration is created with BioRender.com. 
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4.3.1. Particles and Carriers
Chitosan microparticles (CMPs) and nanoparticles (CNPs) are often used as carriers
in skin therapy and especially in wound healing [135]. These drug delivery systems could
provide prolonged and controlled release, protect the drug from degradation, reduce the
administration frequency, and solubilize the antimicrobial compounds [135]. These parti-
cles and carriers could also display antimicrobial and anti-inflammatory properties [135].
Costa et al. prepared CNPs through ionic gelation with tripolyphosphate and challenged
their in vitro activity against biofilm formation in vancomycin-resistant S. aureus (VRSA),
vancomycin-resistant Enterococcus faecalis, and P. aeruginosa and Acinetobacter baumannii,
in addition to the clinical strains of multiresistant A. baumannii and resistant P. aeruginosa.
The CNPs inhibited biofilm formation in all strains; however, the effect was reduced in
VRSA compared to the other strains. Resistant strains of A. baumannii and P. aeruginosa
were more sensitive to the CNPs than the nonresistant strains [136]. In another study,
Hajji et al. evaluated the antimicrobial activity of CNPs loaded in gelatin/chitosan films
against Bacillus cereus, S. aureus, Micrococcus luteus, E. coli, Klebsiella pneumoniae, Salmonella
enterica, Salmonella typhimurium, and Enterobacter spp. bacterial strains. The films loaded
with CNPs exhibited higher antimicrobial activity in a concentration-dependent man-
ner against most strains, especially Gram-positive strains, compared with the unloaded
films [137]. Furthermore, Vila-Sanjurjo et al. tailored genipin and tripolyphosphate dual
crosslinked CNPs and demonstrated quorum quenching activity in E. coli. Blocking the
quorum sensing activity could potentially improve the antibiofilm effect of this type of
drug delivery system [138].
In addition to being utilized for their intrinsic antimicrobial activity, CNPs are used
as carriers for both conventional and traditional antimicrobial compounds from natural
sources such as plants. Curcumin is a polyphenol utilized in wounds because of its antibac-
terial, anti-inflammatory, and antioxidative effects [139]. Due to the limited solubility and
bioavailability of curcumin, CNPs have been utilized to improve curcumin’s antimicrobial
and wound healing properties [65,140]. Basit et al. proposed curcumin-CNPs against
two common skin pathogens, namely S. aureus and P. aeruginosa. The authors demon-
strated concentration-dependent antibacterial activity from both curcumin-containing and
curcumin-free CNPs in both strains; however, curcumin-containing CNPs displayed su-
perior activity [140]. Similarly, Saranya et al. utilized CMPs conjugated with curcumin
against S. aureus and E. coli to prevent skin infections. The CMPs with curcumin had an
increased inhibition zone and improved inhibition in serial dilution than curcumin alone
in both strains [65].
Along with curcumin, other polyphenols have been utilized to treat skin infections.
Fras Zemljič et al. prepared CNPs and CMPs with catechin and resveratrol to enhance
microbial eradication and improve wound healing. These particles were embedded in
poly(ethylene oxide) (PEO) nanofibers and challenged against S. aureus and E. coli. The re-
ported reduction of bacteria was over 83 and 99% for S. aureus and E. coli, respectively [141].
Other compounds from natural sources were also used in CMPs and CNPs. Propolis-
CMPs inhibited biofilm formation and improved eradication of preformed biofilm in E.
faecalis [142], melatonin loaded in chitosan/poloxamer NPs demonstrated antibiofilm
activity against S. aureus. The methicillin-resistant S. aureus (MRSA) [143], essential oil
of Homalomena pineodora in CNPs, generated greater inhibition zones in a range of Gram-
positive and Gram-negative bacteria as well as yeasts [144], and CNPs with Henna extract
improved antimicrobial activity against S. aureus and C. albicans [145].
The proteins, peptides, and compounds generating reactive oxygen species were also
used as antimicrobial compounds in topical skin infections. Aramwit et al. compared the
antimicrobial activity of sericin-loaded CNPs and a commercially available silver wound
dressing in several Gram-positive and Gram-negative bacteria. In the Gram-positive strains,
the sericin-loaded CNPs exhibited superior antibacterial activity [146]. Antimicrobial pep-
tides are considered promising compounds as a solution to AMR challenges. Peptides from
both cathelicidin and temporin families have been incorporated into CNPs [64,147,148].
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OH-CATH30 loaded in carboxymethyl CNPs displayed strong antibacterial activity against
E. coli [148], and LL-37 loaded in CNPs demonstrated complete bacterial eradication after
seven days in a MRSA-infected wound model in mice [64]. Similarly, temporin B loaded in
CNPs exhibited superior antibacterial activity against both a reference strain and clinical
strains of E. epidermidis [147].
The compounds that generate reactive oxygen species, such as photodynamic agents,
are considered promising in AMR [149]. Utilizing photodynamic therapy, indocyanine
green was entrapped in CNPs and challenged against A. baumannii in a biofilm model.
The treatment was superior to all other therapies against the biofilm [150]. Biofilms create
substantial challenges in treating infected skin and especially wounds; thus, several studies
on the antibiofilm effects of chitosan-based delivery systems and scaffolds are summarized
in Table 1.
Table 1. Chitosan-based delivery systems and scaffolds in biofilm eradication for localized antimicrobial therapy. The MW
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In vitro antibiofilm activity:
The lipid-polymer hybrid nanovesicles with vancomycin









In vitro antibiofilm activity:
The zinc-loaded microneedles displayed superior
antibiofilm activity in a concentration-dependent
manner. In the highest zinc concentrations, almost all
bacteria were killed. The unloaded microneedles killed
more bacteria than the control but were less effective










In vitro antibiofilm activity:
The chitosan/poloxamer hydrogel displayed moderate
but significant antibiofilm activity; however, no
additional antibiofilm effects from methylene blue
were observed.
[157]














In vitro antibiofilm activity:
Compared to the control, the chitosan matrix with silver
NPs and silver NPs alone reduced the number of viable









In vitro antibiofilm activity:
The ciprofloxacin-loaded films comprising chitosan and
bacterial cellulose eradicated bacteria within 1 h of
treatment. Inhibition towards both strains; however,










In vitro antibiofilm activity:
The hydrogels comprising chitosan and HPMC with
toluidine blue O displayed good anti-biofilm activity in
biofilms produced by S. aureus or P. aeruginosa with 1- to













In vitro antibiofilm activity:
The peptide-loaded hydrogels had strong anti-biofilm
activity in P. aeruginosa and MRSA, especially in
P. aeruginosa, where the formulation was superior to a
commercialized silver product.
Ex vivo porcine antibiofilm activity:
The peptide-loaded hydrogels surpassed the commercial
product in all three strains and exhibited a strong











Ex vivo antibiofilm activity:
The ε-poly-L-lysine loaded hydrogels reduced the
thickness of the polymicrobial biofilm and reduced the
bacterial load of P. aeruginosa; however, the bacterial










The silver NP-loaded chitosan hydrogel significantly
reduced the bacterial load of MRSA in all concentrations
of the nanoparticles. The bacterial load of P. aeruginosa
was also reduced; however, the reduction was lower than














In vitro antibiofilm activity:
The unloaded hydrogel demonstrated anti-biofilm
activity against both S. aureus and E. coli. The
enzyme-loaded hydrogel had approximately the same
level of inhibition.
[164]
















In vitro antibiofilm activity:
Slightly improved activity from MMW chitosan with










In vitro antibiofilm activity:
Almost all membranes displayed significant antibiofilm
effects both upon evaluating the growth on the dressings
and in wells.
[166]
The n.a. refers to not applicable/not denoted; CNP: chitosan nanoparticles, DDA: degree of deacetylation, HMW: high molecular weight,
LMW: low molecular weight, MDR: multi-drug-resistant MIC: minimum inhibitory concentration, MMW: medium molecular weight,
HPMC: hydroxypropyl methylcellulose, MRSA: methicillin-resistant S. aureus, MRSE: Methicillin-resistant S. epidermidis, MW: molecular
weight, NPs: nanoparticles.
Chitosan-based MPs and NPs have also been utilized to improve the activity of
conventional antimicrobial compounds. Silver sulfadiazine, commonly used in localized
skin infections, has been incorporated in both MPs and NPs [167–169]. Silver sulfadiazine
loaded in CNPs used as a coating on cotton gauzes displayed antimicrobial activity against
Bacillus subtilis, S. aureus, E. coli, P. aeruginosa, and C. albicans [167], and silver sulfadiazine
loaded in CMPs embedded in a PEGylated fibrin gel demonstrated antibacterial activity
S. aureus and P. aeruginosa under in vitro conditions [169] as well as a superior antibacterial
activity after 11 days in a P. aeruginosa-infected porcine model [168].
Cerchiara et al. reported the superior antibacterial effect of vancomycin loaded
in CNPs embedded in Spanish Broom fibres compared with vancomycin alone against
S. aureus [170]. Erythromycin loaded in CNPs embedded in cellulose acetate nanofibers sim-
ilarly demonstrated a more significant inhibition zone in S. aureus, E. coli, and P. aeruginosa
compared with the erythromycin in cellulose acetate nanofibers [171]. Niamlang et al.
showed inhibition of S. aureus, E. coli, and E. faecium within 24 h upon embedding
tetracycline-loaded CNPs in PVA films [66].
Various chitosan-based particles are used to incorporate conventional antifungal
compounds, whereas the use of these particles to include antiviral compounds is scarce.
Recently, Khalid et al. utilized NPs comprising chitosan and chondroitin sulfate as a
delivery system for fluconazole aimed for dermal application against C. albicans. With these
fluconazole-loaded CNPs, the burden of C. albicans was significantly reduced compared
with the fluconazole alone, with approximately a 100-fold reduction of the yeast count [172].
Donalisio et al. tailored nanospheres with chitosan, mineral oil, dodecanol, and surfactants
loaded with acyclovir against the Herpes simplex virus. Compared with acyclovir alone, the
loaded nanospheres had higher antiviral activity against both strains [99].
4.3.2. Coating Material and Excipients
Chitosan is often used to improve the biological or physical properties of the formula-
tion. A broad range of research includes chitosan as an excipient or as a coating material
for formulations intended for the treatment of skin infections. For example, chitosan was
exploited for its bioadhesive properties as a lipid–polymer hybrid carrier of tea tree oil
to improve wound healing. The antimicrobial activity of this formulation was further
tested against P. aeruginosa, S. aureus, MRSA, and C. albicans. The hybrid carriers did not
impede the activity of tea tree oil, and neither was it improved by the inclusion of the
polymer [173].
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The chitosan-shelled/decafluoropentane-cored oxygen-loaded nanodroplets were
tailored to improve microbial eradication in chronic wounds. Both oxygen-loaded and
unloaded nanodroplets significantly inhibited C. albicans; however, inhibition of MRSA
was only observed during the first 4 h [174].
Rosmarinic acid loaded in chitosan encapsulated graphene NPs were challenged
against S. aureus. The minimum inhibitory concentration (MIC) of the loaded NPs was
found to be 0.00681 mg/mL, while the MIC of rosmarinic acid and chitosan was 0.8 and
0.08 mg/mL, respectively. The zone of inhibition was also improved in the NP formulation
(13.3 mm) compared to the rosmarinic acid (12.4 mm) and chitosan (8.7 mm) after 48 h [175].
In another study, the beads comprising PVA and chitosan were utilized to incorpo-
rate zinc oxide NPs. Alongside improved healing rates in a murine model, the in vitro
antimicrobial activity of the zinc oxide-loaded beads was superior to unloaded beads and
chitosan [176].
Zan et al. utilized chitosan/poly(ethylenimine) microneedles loaded with ampho-
tericin B against fungal skin infection. The microneedles were challenged in C. albicans-
infection murine model and reduced fungal burden [177]. In microneedle systems, chitosan
could be utilized in the internal segment of the delivery system, as exemplified by Permana
et al. In this microneedle system, chitosan was used as NPs or coating on PCL, MPs, PCL,
or PLGA with NPs further embedded in PVA/poly(vinyl pyrrolidone) (PVP) microneedles.
The MPs were loaded with silver NPs [178], while the NPs were loaded with doxycycline
as antimicrobial compounds [153]. For the microneedle system loaded with silver NPs, the
antibiofilm activity was evaluated in an ex vivo biofilm model with S. aureus or P. aeruginosa.
Here, the silver NPs loaded in MPs embedded in microneedles eradicated 100% of the
biofilm for both strains and showed superiority to all tested formulations [178].
Several studies utilized chitosan as a coating, especially for NPs. Azzazy et al. utilized
chitosan-coated PLGA NPs loaded with Peganum harmala alkaloids for antibacterial proper-
ties and wound healing. In this study, the chitosan-coated NPs were challenged against
S. aureus and E. coli using in vitro broth dilution method. The loaded chitosan-coated NPs
improved the antibacterial potential against E. coli and S. aureus [179]. In another research
effort, chitosan-coated NPs comprising PLGA and PVA loaded with benzalkonium bromide
were evaluated in an in vitro biofilm assay and an in vivo murine MRSA-infected wound
model. The coated NPs displayed a significantly improved inhibition of biofilm formation
compared with free benzalkonium bromide, as well as a reduced bacterial burden in the
in vivo wound model [180].
Metal-based NPs are also frequently seen in delivery systems intended to eradicate
microorganisms in skin and wounds. Daghian et al. designed a hybrid drug delivery
system comprising silver and talc capped with chitosan to improve the healing of infected
wounds. The authors tested the MIC and minimum bactericidal concentration (MBC)
against S. aureus, P. aeruginosa, Streptococcus pyogenes, and E. coli. Additionally, the hybrid
system was challenged against a murine P. aeruginosa and S. aureus-infected wound model
and compared to mupirocin ointment. In the in vivo wound challenge, the bacterial burden
in the mice treated with either mupirocin or the chitosan-capped hybrid system was
lowered compared with the control noncapped hybrid system and talc. After 14 days, all
other groups, except the control, had an extensive reduction of the bacterial burden [181].
The in vivo studies are important as a translational step to more marketed products and the
use of chitosan in the fight against AMR. Therefore, studies with in vivo data on chitosan-
based delivery systems and scaffolds are summarized in Table 2. In another research
effort by Verma et al., tailored sericin and chitosan-capped silver NPs also improved
wound healing and antimicrobial activity. Additionally, the capped silver NPs embedded
in hydrogel demonstrated improved wound closure compared to a marketed povidone–
iodine ointment and no dermal irritation [182]. The chitosan-capped copper oxide and
copper NPs were prepared as composite films and challenged against E. coli and Bacillus.
All formulations exhibited antimicrobial activity against both strains [183].
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MRSA-infected wound model in mice:
No growth of MRSA was observed in the group
treated with LL-37 loaded CNPs after 7 days.









S. aureus-infected wound model in rats:
CNPs loaded with cefadroxil embedded in in situ
poloxamer 407 hydrogel showed a significant
reduction in the bacterial burden in the wounds









MRSA-infected wound model in mice:
the rats treated with pH-responsive CNPs
comprising gemini surfactants loaded with
vancomycin displayed a significantly reduced
bacterial burden compared with both drug-free








Noninfected wound model in mice:
The bacterial growth in the wound without
induced infections treated with any of the
chitosan/PVA/zinc beads was lower than the
control. Almost no growth was observed in mice














S. aureus-infected wound model in rats:
the rats treated with the chitosan-functionalized
quantum dots composite together with
illumination exhibited improved wound healing










C. albicans-infected wound in rats:
chitosan hydrogel loaded with vesicles
comprising penetration enhancers produced a











P. aeruginosa-infected wound in a murine model:
β-cyclodextrin modified chitosan supramolecular
hydrogel loaded with diclofenac and silver ions
displayed improved wound healing and reduced
the bacterial load in the wound bed.
[188]



















S. aureus-infected wound model in mice: The
chitosan/ion hydrogel in gauzes surpassed
chitosan alone and the control group in wound
healing. Additionally, the group treated with the
chitosan/ion hydrogel in gauzes significantly
reduced bacterial load in the wound bed








S. aureus-infected burn and wound model in mice:
The healing rate of the wounds treated with the
silver sulfadiazine nanocrystal in the hydrogel
was faster, and the overall healing was superior












Polymicrobial wound model in rats:
The ciprofloxacin and fluconazole-loaded fibrin
NPs loaded in chitosan hydrogel bandage
displayed a significant reduction in microbial
load in the infected wound compared to the
unloaded- fibrin NPs loaded in chitosan.













MRSA biofilm-infected wound model in mice:
The hydrogel loaded with antimicrobial peptide
and hydrogen peroxide displayed a significant
reduction in bacterial viability compared to all
other treatments; however, not complete
eradication. Chitosan alone reduced
bacterial viability.
Wound closure also improved in the groups









MRSA biofilm-infected wound model in mice:
Both loaded and unloaded chitosan films reduced
the bacterial burden in the wound and improved
the healing rate compared to the control group.
However, the NO-releasing film displayed a









MRSA-infected wound model in rats:
The bacterial load in the group treated with the
catechol-chitosan film at a reduced state was
significantly reduced compared with the other










MRSA-infected wound model in mice:
Chlorinated chitosan film produced with
electrofabrication induced faster wound healing
and reduced the wound’s bacterial burden,
compared to the control and plain chitosan.
[195]














S. aureus and P. aeruginosa infected-wound
model in rats:
The membranes significantly reduced the
bacterial load in the wounds compared to the








P. aeruginosa-infected wound model in mice:
The mice treated with the polyelectrolyte
complex had a reduced bacterial load in the
tissue after 14 days of treatment and higher








MRSA-infected wound model in rats:
The indocyanine green-loaded chitosan/PVA
nanofibers and illumination demonstrated
improved wound healing and reduced bacterial











S. aureus and E. coli-infected wound model in rats:
The group treated with gelatin microspheres
loaded with gentamycin and platelet-rich plasma
on chitosan dressing displayed reduced bacterial
load and a faster wound healing rate than the









S. aureus-infected wound model in mice:
The group treated with the graphene
oxide–copper composite in chitosan/hyaluronic
acid hydrogel improved wound healing








S. aureus-infected wound model in rabbits:
the group treated with the silver NP-sponge
healed faster than the control group, and
although not statistically significant, faster than









S. aureus-infected wound model in mice:
the chitosan sponges loaded with quaternary
ammonium CNPs exhibited superior
antimicrobial activity compared to sponges
without CNPs and untreated mice on days
7 and 10.
[202]
n.a.: not applicable/not denoted; CNP: chitosan nanoparticles, DDA: degree of deacetylation, LMW: low molecular weight, MMW: medium
molecular weight, MRSA: methicillin-resistant S. aureus, MW: molecular weight, PVA: poly(vinyl alcohol).
In addition to these inorganic materials, chitosan could be utilized as a coating for
lipid-based systems, such as liposomes. This approach was used by Alshaman et al.,
where dicloxacillin was incorporated in chitosan-coated liposomes to improve the eradica-
tion of MRSA. The drug-loaded chitosan-coated vesicles were able to reduce the burden,
whereas drug-free chitosan-coated and noncoated liposomes did exert some antimicrobial
activity [203].
In addition, other oil-based formulations could also be used. Kumari and Kesavan
evaluated clotrimazole-loaded microemulsions comprising clove oil, Tween 80, and propy-
lene glycol coated with chitosan to improve the therapy of superficial fungal infections. The
microemulsion system was challenged against C. albicans. Both the coated and noncoated
microemulsions displayed antimicrobial properties. Furthermore, the authors evaluated
Mar. Drugs 2021, 19, 697 17 of 53
skin retention of the coated and noncoated microemulsion, and these results revealed
that almost 70% clotrimazole from the coated microemulsion remained in the skin after
eight hours, while less than 40% remained after administering the noncoated emulsion.
Retention in the skin is essential for topical therapeutical delivery to the skin [204].
Sandri et al. and Sun et al. combined chitosan with montmorillonite to increase
antimicrobial eradication in the skin and wound infections [205,206]. The MBC of silver sul-
fadiazine loaded into the chitosan-containing composite against Gram-negative E. coli and
P. aeruginosa was lower compared with the composite without chitosan [205]. The bacterial
burden was lowered in an in vivo murine S. aureus-infected wound model upon treat-
ment with 5-fluorocytosine loaded in chitosan-containing composite [206]. Furthermore,
as an excipient, chitosan has been combined with nanofibers [207–209], gauzes [36,189],
graphene quantum dots [186], and as a powder [210] or matrix for immobilization of
enzymes [165,211] to improve antimicrobial properties and wound healing.
4.3.3. Polymer-Based Gels
The gels and hydrogels are frequently used both as antimicrobial vehicles and drug
delivery systems in localized drug therapy. In addition to serving as a drug carrier with
prolonged or controlled release, gels maintain the moisture balance in skin lesions and
wounds and provide bioadhesive properties to ensure retention at the intended site [212].
The cryogels are frequently developed as drug delivery systems for microbial eradication
and treatment of skin infections. Due to the macroporous structure, they are both flexible
and elastic and could improve the wound healing process [213]. Bölgen et al. applied
this strategy to enhance the eradication of a broad range of microorganisms commonly
found on the skin. The authors prepared Hypericum perforatum oil-loaded chitosan cryogels
crosslinked with glutaraldehyde and further evaluated the antimicrobial potential of the
delivery system using the disc diffusion method. The results revealed antimicrobial activity
against all strains, namely Enterococcus hirae, B. cereus, S. aureus, E. coli, Legionella pneumophila
subsp. Pneumophila, P. aeruginosa, and C. albicans, in a concentration-dependent manner.
Additionally, the oil-loaded cryogel displayed an antioxidative effect and could potentially
serve as a free radical scavenger [213].
In another research effort, Hou et al. tailored cryogels comprising glycol chitosan
methacrylate and ε-poly-lysine acrylamide to improve eradication of resistant S. aureus
in the wound bed. In the in vitro studies, the cryogel eradicated >99% of MRSA and
E. coli, while in the in vivo MRSA-infected wound model, the mice treated with cryogel
showed no signs of infection and improved wound closure [214]. Han and colleagues
prepared cryogels combining chitosan and silk fibroin for improved mechanical strength.
They used polydopamine NPs as near-infrared absorbing agents to improve antimicrobial
properties and modulate the wound healing process. The cryogel with NPs, along with
near-infrared irradiation, exhibited superior antibacterial properties, especially in the
elevated NP concentrations. Furthermore, the cryogel with NPs also displayed superior
anti-oxidative properties [215].
Aerogels are not as commonly used in antimicrobial eradication in skin infections and
wound healing. Nevertheless, López-Iglesias et al. developed a novel chitosan aerogel
loaded with vancomycin using a jet cutting technique. The antibacterial activity of the
aerogel was evaluated using S. aureus. The aerogel demonstrated antibacterial activity
and facilitated complete eradication in six hours, with the effect lasting for two days.
Additionally, the aerogel could absorb nine times of its weight moisture in the wound
bed [216].
Among the polymer-based gels, hydrogels are most frequently used in topical, antimi-
crobial skin therapy. Hydrogels provide good water balance in the wound bed, control the
release of antimicrobial compounds, and allow oxygen exchange [19,217]. Ouyang et al.
incorporated a marine peptide from seawater cultured tilapia in chitosan hydrogels. In
the in vitro antimicrobial evaluations, the peptide-loaded hydrogel inhibited both S. aureus
and E. coli [218].
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More conventional antimicrobial compounds have also been loaded into chitosan
hydrogels. Gentamicin-conjugated chitosan hydrogel was tailored as a scald dressing.
In an in vitro disc diffusion assay, the gentamicin-grafted chitosan hydrogel displayed
significant inhibitory activity against both strains compared to chitosan alone. In S. aureus,
the inhibitory activity was superior to gentamicin alone [219].
El-Kased et al. proposed comparing polyacrylic acid and chitosan hydrogels as
delivery systems for honey. Honey was loaded into the hydrogels, and antibacterial
properties were assessed against P. aeruginosa, S. aureus, S. pyogenes, and K. pneumonia.
In vitro disc diffusion tests proved antimicrobial activity from both chitosan and polyacrylic
acid; however, the antimicrobial activity from hydrogels with chitosan was superior, and
the activity increased with increasing honey concentrations. Only moderate activity was
observed from the honey alone. In the in vivo murine burn wound model, no bacterial
growth occurred in the noninfected wounds [220].
Along with studies on the antibacterial activity of chitosan hydrogel, studies on
the antifungal activity have been performed. Özcan et al. incorporated terbinafine in
chitosan hydrogels containing chitosan of different MW. All chitosan hydrogels loaded
with terbinafine displayed antimicrobial activity against a wide range of filamentous fungi
and Candida spp. Chitosan hydrochloride hydrogel exhibited the strongest inhibitory
effect along with the fastest terbinafine release. The antimicrobial activity was superior
to the action of a marketed product and similar to free terbinafine. In general, lower MW
corresponded with higher antifungal effects [221].
To improve the responsiveness of the hydrogels, researchers have proposed using
crosslinkers to tailor pH or thermal responsiveness in the hydrogel network [162,222,223].
To prepare pH-responsive hydrogel, designed for the altered pH in the wound bed, Heim-
buck et al. utilized a combination of chitosan and genipin. Two chitosans with different
MW were used in the evaluation, namely 15 and 50−190 kDa. In the antimicrobial evalua-
tion of the hydrogels, the activities of two chitosan hydrogels were compared to chitosan
films in E. coli. The films reduced the bacterial load by approximately 90%, while the
chitosan-genipin hydrogels reduced growth by approximately 70%; no differences were
observed between chitosan with lower and higher MW [222].
Introducing thermal responsiveness into the hydrogel network, researchers have
utilized the crosslinker β-glycerolphosphate, as exemplified by Pati et al. [162] and Rezaei
et al. [223]. Pati and colleagues proposed thermal responsive hydrogel loaded with 0.5 or
1% (w/v) ε-poly-L-lysine in the eradication of monomicrobial and polymicrobial biofilms
in wounds produced by clinical isolates. In the in vitro monomicrobial biofilms, ε-poly-
L-lysine loaded hydrogels eradicated >99% of P. aeruginosa and >70% of MRSA, while
no antimicrobial activity was observed against C. albicans. In the ex vivo polymicrobial
biofilm model, the loaded hydrogels significantly reduced the thickness of the biofilm and
reduced the bacterial load of P. aeruginosa compared with the untreated biofilm; however,
no reduction was observed for MRSA or C. albicans. The authors postulated that some
bacteria were observed on the side of the biopsy and were therefore not in contact with the
hydrogel [162]. Rezaei et al. prepared thermal responsive hydrogel to load the antimicrobial
peptide Piscidin-1 to improve the eradication of clinical isolates of resistant A. baumannii.
The standard strain of A. baumannii was inhibited by hydrogels loaded with 4 µg/mL of
the peptide, while the clinical isolate required loading of 16 µg/mL before an inhibition
zone was observed [223].
Chitosan hydrogels are often criticized for their mechanical properties. Introducing
additives or combining chitosan with other polymers might improve those mechanical
properties [20]. Masood et al. combined chitosan with polyethene glycol (PEG) in hydrogels
loaded with silver NPs. Here, PEG served as a stabilizing agent in the hydrogel to increase
swelling abilities and structure. The investigations of the antimicrobial activity against
E. coli, P. aeruginosa, B. subtilis, and S. aureus showed that the silver NP-loaded hydrogels
exhibited improved activity compared with silver NPs alone and chitosan hydrogel. The
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silver NP-loaded hydrogel also exhibited improved in vivo wound healing in a rabbit
wound model with 48% wound closure after only four days [224].
Another potential drawback with hydrogels is burst release from the hydrogel network.
This drawback could be contacted by using a primary vehicle in the hydrogel, such as
lipid-based vesicles, NPs, or other carriers (Figure 3). Additionally, these vesicles could
improve the release profile of the delivery system [225]. Utilizing soy lecithin, Hemmingsen
et al. prepared chlorhexidine-loaded liposomes embedded in chitosan hydrogel intended
to treat chronic wounds. The antibiofilm activity of the loaded liposomes in the hydrogel
was evaluated against S. aureus, P. aeruginosa, and a clinical isolate of S. aureus, where both
the inhibition of biofilm formation and eradication of preformed biofilm were tested. The
dual drug delivery system almost completely inhibited the formation of biofilm in both
S. aureus and P. aeruginosa. Furthermore, the dual delivery system displayed strong in vitro
anti-inflammatory properties [226].




Figure 3. Concept of the primary and secondary vehicles to avoid some limitations of hydrogels 
represented as nanoparticles (primary) in hydrogel (secondary). The illustration is created with Bi-
oRender.com. 
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Similar y, Sohrabi et al. prepared moxifloxacin-loaded niosomes embedded in LMW
or MMW chitosan hydrogels. The antimicrobial activity of the dual delivery system
comprising the medium MW chitosan was evaluated against S. aureus and P. aeruginosa.
The niosomes appeared to improve the antimicrobial activity of moxifloxacin against
P. aeruginosa; however, the smallest inhibition zones in both strains were observed for the
dual system. On the other hand, the MIC values for the dual system and the moxifloxacin-
loaded hydrogel were lowered in S. aureus compared to the different formulations and free
drugs [227]. The strategy of utilizing vesicles embedded in hydrogels has also been tested
against fungi, as in the work of AbdelSamie and colleagues [187].
4.3.4. Scaffolds
Among the scaffolds, films and membranes are among the most common in the ther-
apy of skin infections and infected wounds. These films have some beneficial properties,
making them suitable for use in skin lesions and wounds. They allow for oxygen exchange
and moisture evaporation simultaneously as they protect the area from contamination
of bacteria from the external environment. Additionally, they are very flexible, allowing
for easy application onto the skin and adaptation to the specific area of the body. Fur-
thermore, they protect the incorporated compound until it is released into the intended
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area [228]. Pereira dos Santos and colleagues incorporated clove or melaleuca essential
oils into chitosan films aimed at wound healing applications and eradicating bacteria and
yeast. The authors evaluated the in vitro antimicrobial activity of the emulsion of the film
composition against S. aureus, E. coli and C. albicans. The inhibition was lowered upon
treatment with film emulsion compared to the essential oils alone. However, chitosan alone
displayed antimicrobial activity against all strains [229]. In another study by Altiok et al.,
using thyme oil in chitosan films, the inhibition zone obtained in S. aureus, P. aeruginosa,
K. pneumoniae, and E. coli were more significant. The chitosan films without oil did not have
any antimicrobial effect [230]. Altiok and colleagues used higher chitosan concentrations
and LMW chitosan, while Pereira dos Santos and colleagues used MMW chitosan. The
DDA was approximately the same in these studies.
Other antimicrobial compounds from natural sources are also utilized in chitosan films
for skin infections, such as capsaicin and curcumin. Akyuz and colleagues incorporated
capsaicin into chitosan films with glycerol as a plasticizer and assessed the antimicrobial
of three different concentrations in three Gram-positive and six Gram-negative strains.
The loaded film showed antibacterial activity against all strains but seemingly higher
activity against Gram-negative bacteria. Additionally, the loaded film displayed antiquo-
rum sensing activity in Chromobacterium violaceum [231]. Upon loading with curcumin,
Muthulakshmi and Rajarajeswari combined chitosan and pectin in the films. These films
were assessed against S. aureus and E. coli and showed antibacterial activity against both
strains. However, no activity was observed for curcumin-free films [232].
Chitosan films were also combined with more conventional antimicrobial compounds
to treat skin and wound infections. Kausar and colleagues combined chitosan films with
vancomycin to eradicate MRSA in burn wounds. The chitosan film with the highest
vancomycin concentration (20%) showed the strongest antibacterial effect in a disc diffusion
assessment compared with blank chitosan film, films loaded with lower concentrations of
vancomycin (10%), and free drugs. Similar results were obtained in microdilution tests. In
an in vivo rat wound model, the group treated with vancomycin-loaded films displayed
the fastest wound healing with no detected bacterial growth [233].
Bavarsad et al. utilized griseofulvin to treat superficial fungal skin infections. Griseo-
fulvin was loaded in liposomes embedded in chitosan films. These films were evaluated
against Microsporum gypseum and Epidermophyton floccosum and showed antimicrobial
activity in both strains, exhibiting the highest permeation across mice skin [234].
Ambrogi and colleagues combined montmorillonite with chitosan in composite films
and utilized chlorhexidine diacetate as an antimicrobial compound. The film was chal-
lenged against S. aureus, S. epidermidis, P. aeruginosa, and C. albicans. All chlorhexidine
films displayed antimicrobial activity in all strains; however, the activity was stronger in
Gram-positive bacteria. Plain chitosan films had a moderate effect on the Gram-positive
bacteria and C. albicans. The composite film without chlorhexidine had no activity in
any of the strains. Almost all composite films loaded with chlorhexidine had a superior
antibiofilm activity [235].
Silver sulfadiazine is, as mentioned, a common compound used in the treatment of
skin infections. Hissae Yassue-Cordeiro et al. impregnated zeolite with silver sulfadi-
azine and tailored a zeolite–chitosan composite film. The antimicrobial activity against
S. aureus was lacking; however, the films exhibited activity against E. coli, P. aeruginosa, and
C. albicans [236].
Other film formulations have been utilized for the treatment of skin infections. Silver
NPs are commonly used and often display promising antimicrobial efficacy. Studies
incorporating silver NPs in chitosan films have shown activity against E. coli [237–239],
Bacillus sp. [238,239], and K. pneumonia [239]. In addition to utilizing chitosan films as
vehicles, Pansara and colleagues stabilized silver NPs with chitosan and embedded these
particles in chitosan films. These films demonstrated antibacterial activity against E. coli in
in vitro conditions as well as faster wound closure in the E. coli-infected wound model in
rats [240].
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Wang and colleagues utilized gold NPs to increase the antibacterial potential of chi-
tosan films against S. aureus and E. coli. The modification with gold NPs significantly
improved the antibacterial activity of the chitosan films against both S. aureus and E. coli.
Additionally, the modified film improved wound healing in a noninfected wound model
in rats, further proving the potential of these films as wound healing scaffold [241]. Addi-
tionally, other inorganic agents have been utilized to improve the antimicrobial potential
of chitosan films. Hanafy et al. incorporated TiO2 NPs into chitosan film for the intended
use in dermal wounds. These films were assessed against a range of bacteria and fungi
with promising results. Both loaded films and films without NPs displayed activity against
B. cereus, S. aureus, E. coli, C. albicans, and Aspergillus niger. In C. albicans, the film without
NPs showed higher antimicrobial activity than the loaded films [242].
Foster and Butt found no antimicrobial activity of unloaded chitosan films compared
to chitosan in solution against S. aureus, S. epidermidis and E. coli. Their films existed in
a dry state and were unable to interact with the bacterial cells. However, the MW of the
chitosan used in this study is not reported [243].
Films and membranes are often prepared in combination with other polysaccharides
to improve either antimicrobial activity or mechanical properties. Archana et al. prepared
scaffolds based on chitosan and pectin. These scaffolds were loaded with TiO2 nanorods
and assessed against S. aureus, E. coli, P. aeruginosa, B. subtilis, and A. niger. The combination
of chitosan and pectin and TiO2 nanorods exhibited excellent antimicrobial activity against
all strains but with higher activity in bacteria [244]. Gómez Chabala et al., along with Bueno
and Moraes, prepared scaffolds comprising chitosan and alginate. These scaffolds loaded
with either silver NPs and aloe vera [245] or polyhexamethylene biguanide [246] both
expressed antimicrobial activity against S. aureus; however, only the scaffold loaded with
silver NPs and aloe vera displayed antimicrobial activity against P. aeruginosa [245,246]. Ke-
nawy and colleagues tailored chitosan/gelatin scaffolds loaded with cinnamaldehyde and
assessed their antimicrobial activity against S. aureus, P. aeruginosa, Salmonella, and E. coli.
These scaffolds demonstrated antimicrobial activity in a cinnamaldehyde dose-dependent
manner against all strains. The effect was generally higher against the Gram-negative
strains [247]. Furthermore, chitosan has been utilized in combination with hyaluronan to
produce scaffolds loaded with phosphatidylcholine dihydroquercetin. These scaffolds were
challenged against E. coli, K. pneumoniae, S. aureus, and Staphylococcus haemolyticus. The
antimicrobial activity of the loaded scaffolds was superior to the unloaded scaffold against
all strains. The loaded scaffolds showed good anti-inflammatory and wound healing
properties [248].
Many studies focus on sponge-like scaffolds and nanofibers to accommodate cell
migration and wound closure. Zhou and colleagues prepared a sponge-like scaffold loaded
with silver NPs and iturin, and cyclic lipopeptide and evaluated the antibacterial and anti-
fungal effect of these formulations. In the in vivo antibacterial evaluation in E. coli-infected
wounds in mice, the scaffold reduced the bacterial burden and demonstrated good wound
healing properties. In C. albicans-infected wounds, the scaffolds also improved wound
healing in mice [249,250]. Silver sulfadiazine is also utilized as antimicrobial compounds
in these sponge-like scaffolds. Shao et al. tailored silver sulfadiazine particle scaffolds and
challenged their antimicrobial potential against E. coli, S. aureus, B. subtilis, and C. albicans.
The unloaded scaffolds had no antimicrobial effect on the microorganisms, but the loaded
scaffolds had good antimicrobial activity in all strains in a concentration-dependent man-
ner [251]. Dumitriu and colleagues prepared chitosan–hyaluronate sponge-like scaffolds
and tailored polyelectrolyte complex between the scaffold and sulfadiazine. The complex
was assessed against Salmonella, Listeria monocytogenes, and E. coli. Additionally, the authors
evaluated the activity of LMW and MMW chitosan. The antimicrobial evaluation showed
that both the LMW and MMW chitosan-based complexes had excellent antimicrobial
activity against all strains; however, the LMW chitosan had better activity [252].
Hamblin et al. have extensively evaluated sponge-based bandages produced with
chitosan acetate for their use in infected and burn wounds. Across different studies, this
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scaffold has been evaluated in vivo against S. aureus, P. aeruginosa, and Proteus mirabilis-
infected wounds and burn injuries. It proved promising in all these wound infections and
suitable as a scaffold in burn wound healing [253–255].
The PEO is commonly utilized together with chitosan to produce nanofibers. Chitosan–
PEO nanofibers loaded with either teicoplanin [256] or vancomycin [257] have been used
as scaffolds in wound healing. Here, the antibacterial potential of these fibres was assessed
against S. aureus. Upon loading nanofibers with teicoplanin, the antimicrobial activity was
significantly stronger than the free compound [256]. When loading vancomycin in the
chitosan–PEO nanofibers, the same superior effect was seen against both S. aureus and
MRSA [257].
Faccendini et al. combined chitosan with pullulan and either chondroitin sodium
sulfate or hyaluronic acid and then loaded the nanofibers with montmorillonite norfloxacin
nanocomposite. In the antimicrobial evaluation, the nanocomposite-loaded nanofibers
exhibited antimicrobial activity against both S. aureus and P. aeruginosa; however, the
activity of free norfloxacin in nanofibers was seemingly higher than when the drug was
part of the nanocomposite, possibly due to slower release [258].
The antimicrobial peptide CM11 was loaded into nanofibers comprising chitosan and
silk fibroin aimed at treating infected wounds. This system was evaluated against S. aureus,
E. coli, P. aeruginosa, and resistant strains of the same bacteria. The scaffold itself did not
display any antimicrobial activity; however, the nanofibers loaded with 16 µg/mL peptide
exhibited inhibition against standard strains, while the effect on resistant strains was first
seen at peptide concentrations of 32 µg/mL [259].
Bösiger and colleagues investigated chitosan/PEO nanofibers functionalized with
the enzyme glucose oxidase. The generation of H2O2 could potentially improve microbial
eradication and stimulate fibroblast proliferation. The nanofibers showed inhibition of
both S. aureus and E. coli compared with the control, and this effect was observed already
after two hours [260].
Monteiro and colleagues combined nanofibers with liposomes loaded with gentamicin.
The authors prepared chitosan nanofibers and immobilized gentamicin-loaded liposomes
on the surface of the nanofiber scaffolds. This dual system was assessed against S. aureus,
E. coli, and P. aeruginosa. Neither the chitosan nanofibers nor the nonloaded liposomes
immobilized on nanofibers displayed antimicrobial activity against any bacteria. How-
ever, the gentamicin-loaded liposomes immobilized on nanofibers exhibited a superior
antimicrobial effect against all three strains [261].
5. Chitosan and Vaginal Infections
5.1. Common Vaginal Infections
Various microorganisms, including bacteria, fungi, parasites and viruses, can cause
vaginal infections. Vulvovaginal candidiasis, bacterial vaginosis, and aerobic vaginitis are
the most common endogenous infections. Alarmingly, in an era of AMR, the incidence of
sexually transmitted infections (STIs) such as gonorrhoea, mycoplasma, chlamydia, and
trichomoniasis are continuously on the rise [10].
Candida albicans is an innate part of the vaginal microflora; however, an imbalance in
the normal flora can cause an infection. C. albicans is the most frequent cause of candida
infections, but C. glabrata, C. tropicalis, C. parapsilosis, C. crusei, C. stellatoidea, and C. lusitaniae
strains can cause vulvovaginal candidiasis as well [262]. Up to 75% of all women will
experience a candida infection during their lifetime, of which 50% will experience recurrent
infections despite the existing oral and topical antifungal therapies [263]. Recurrent vul-
vovaginal candidiasis infections are common due to persistent strains, AMR, and biofilm
formation [264].
Bacterial vaginosis is one of the most widespread vaginal infections [10]. An infection
originates from the overgrowth of anaerobic bacteria that are a natural part of the vagi-
nal microflora. These anaerobic bacteria include Bacteroides fragilis, Gardnerella vaginalis,
and Atopobium vaginae, of which B. fragilis is the most resistant strain [265]. Both oral
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(metronidazole and clindamycin, tinidazole and secnidazole) and topical (metronidazole
and clindamycin) antibiotic treatments are currently available; however, they often fail to
completely eradicate biofilms, thus, preventing successful antimicrobial therapy [8,10]. The
persistent biofilm contributes to recurrent infections and might intensify the resistance to
antimicrobial agents [24].
Aerobic vaginitis is caused by a dominance of Lactobacillus that causes abnormal
vaginal microflora containing aerobic pathogens such as Streptococcus agalactiae, E. faecalis,
E. coli, and S. aureus [266]. Aerobic vaginitis and bacterial vaginosis share several common
features, and despite a clear difference, the two conditions often coincide in diagnosis
and literature [267]. There is no standard treatment; however, because aerobic vaginitis
is associated with inflammatory changes, the antibiotic clindamycin with its inherent
anti-inflammatory effect is often preferred [267,268].
Trichomoniasis infection is caused by the parasite Trichomonas vaginalis, a flagellated
protozoan that adheres to the vaginal mucosa generating colonization and persistent
infection [269]. Trichomoniasis is the most common nonviral STI in women of reproductive
age [270]. Oral antibiotic metronidazole is considered the first-line therapy; however, side
effects, contraindication during pregnancy, and drug-resistant parasites affect the use and
effectiveness of current treatment options [271].
Neisseria gonorrhoeae is a Gram-negative, human obligate bacteria that causes genital
gonorrhoea infection [10]. Gonorrhoea is currently the second most common bacterial
STI, with an estimated global incidence of 86.9 million new infections each year [272].
Intramuscular and oral single-dose antibiotics are currently first-line treatments; however,
the continuous rise in AMR is threatening the effectiveness of the available therapy [273].
Mycoplasma genitalium is a highly prevalent STI with rapidly increasing resistance to
the already limited available treatment options [274]. First-line treatment is oral antibiotic
azithromycin; however, M. genitalium is highly prone to the development of AMR, and
both M. genitalium and N. gonorrhoeae might develop into untreatable superbugs in the
future [275].
Chlamydia trachomatis is a small obligate intracellular, Gram-negative bacterium that
is the most common cause of bacterial STIs [276], with an estimated annual incidence of
127 million new infections globally [277]. Moreover, due to the asymptomatic nature of
C. trachomatis infections, the number is believed to be considerably underestimated. The
current treatment is oral antibiotics; however, AMR is expected to limit available therapy
in the future [278].
The majority of vaginal infections are often present as an asymptomatic disease, im-
plying an underestimated number of cases, increased spread, and untreated infections. The
lack of treatment or unsuccessful therapy can lead to reproductive health consequences
and complications in pregnancy, as well as increased risk of acquiring other STIs, including
HIV [10,269,279]. A vaginal infection is often accompanied by coinfection with other sexu-
ally transmitted pathogens, especially in female populations, such as high coinfection rates
by mycoplasma and chlamydia [280]. This further complicates the successful elimination
of infections and contributes to the development of AMR. Hence, there is a need for new
approaches, new antibiotics, and optimized delivery systems that can assure an efficient
local treatment.
5.2. Challenges of Localized Therapy of Vaginal Infections
The vaginal environment presents several challenges for effective localized therapy.
Due to the self-cleansing action of the vaginal tract, locally administered formulations often
fail to persist at the site of action long enough to assure sufficient therapeutic effect [281].
Vaginal pH, the thickness of the epithelium, and the production of vaginal fluid and mucus
all vary, depending on the phase of the menstrual cycle, sexual activity, age, and the
presence of concomitant diseases [282].
Primarily, an adequate residence time at the site of action must be obtained to allow for
therapeutic effect. The successful formulation needs to avoid rapid vaginal clearance, and
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in this regard, chitosan plays an important role, providing mucoadhesive properties and the
possibility of prolonged residence time [70,283]. Moreover, the locally applied formulation
should enable the active ingredient to overcome the vaginal mucus barrier reaching the
vaginal epithelium (infection site) to provide both controlled and predictable release of the
incorporated active ingredient, be uniformly distributed onto the underlying tissue, and
assure a sufficiently high and maintained antimicrobial action over an adequate period
within vaginal cavity [284]. In addition, the system should provide both controlled and
predictable release of the incorporated active ingredient, assuring an improved therapeutic
outcome. If these conditions are met, systemic exposure can be avoided, the required dose
reduced, and the potential for the development of AMR can be limited [10]. Moreover, a
safe treatment should be assured for pregnant patients who currently suffer from a lack of
available treatment for most vaginal infections [44].
5.3. Antimicrobial Chitosan-Based Systems for Vaginal Application
In addition to the excellent mucoadhesive properties provided by chitosan, its intrinsic
antimicrobial properties make it an attractive material in pharmaceutical applications,
including those for localized vaginal therapy [74]. Another quality that chitosan can supply,
of great importance in treating vaginal bacterial inflammation and infections, is the ability
to disrupt bacterial biofilms [24]. The many beneficial properties enable chitosan to act as
an active ingredient, carrier, mucoadhesive excipient, and an amplifier of the antimicrobial
effect by working in synergy with other active ingredients [69].
Substantial research is carried out on chitosan-based applications for vaginal delivery.
In the following sections, the focus is placed on vaginal formulations comprising chitosan,
as active substance, carrier, excipient, hydrogel, or vaginal film, assessed regarding antimi-
crobial activity against common vaginal pathogens. The main findings in the discussed
research are summarized in Table 3.








Clotrimazole Decreased antifungal activity in vitro but improvedsafety profile for CNP-associated clotrimazole [285]
Callophycin A Synergetic and improved antifungal effect bothin vitro and in vivo by Callophycin A in CNPs [286]
Thiosemicarbazide CNP-associated thiosemicarbazide obtained aprominent reduction of fungal burden in vivo [287]
Miconazole
CNPs containing a seven-fold lower miconazole
concentration than conventional miconazole cream




The combination of miconazole and farnesol in CNPs
expressed a greater antifungal effect in vivo [289]
Argentinean
medicinal plants
Chitosan microcapsules containing active substances
exhibited strong antifungal capacity in vitro [290]
Bacterial vaginosis
Doxycycline CNP-associated doxycycline expressed a significantreduction in E. coli viability in vitro [291]
Metronidazole




Aerobic vaginitis Cefixime Cefixime microspheres reduced E. coli viabilityin vitro [292]
Trichomoniasis - CNPs expressed concentrations and time-dependentantimicrobial activity against T. vaginalis in vitro [293]
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Gonorrhoea -
CNPs expressed antigonoccocal activity against all








Chitosan-coated nanocapsules maintained the
antifungal activity for both drugs in vitro [295]
Clotrimazole Chitosan-coated PLGA NPs increased the antifungalactivity of clotrimazole in vitro [296]
Metronidazole
Fungal inhibition was equal for the chitosan-based
formulation containing metronidazole and the
drug-free formulation
[27]
Herbal medicine All constituents of the microemulsion expressedantifungal activity in vitro, including chitosan [297]
Metronidazole
In vitro antifungal activity was increased in the




The hydrogel containing amphotericin B-loaded




Chitosan-based vaginal inserts containing
fluconazole showed improved antifungal activity
both in vitro and in vivo compared to free drug
[300]
Curcumin
Curcumin liquid crystal system containing chitosan
increased the antifungal potency of curcumin in vitro [301]
Curcumin liquid crystal system containing chitosan
significantly decreased fungal burden in vivo and
efficiently reduced the growth of biofilm in vitro
[302]
Fluconazole Chitosan-based vaginal tablets increased theantifungal activity of fluconazole [303]
Chelidonii herba
extract
Chitosan-based vaginal tablets detained the in vitro
antimicrobial activity of the extract [304]
Ketoconazole
Ketoconazole-containing chitosan and gellan gum




Thermosensitive gel with a chitosan gel-flake system




Chitosan-based vaginal inserts increased the
antifungal activity of chlorhexidine in vitro [307]
Chitosan-based vaginal inserts increased the
antifungal activity of chlorhexidine in vitro [308]
Bacterial vaginosis -
Chitosan-coated liposomes expressed in vitro
antibacterial effect against S. epidermidis and S. aureus [8]
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Metronidazole Vaginal tablets containing chitosan andmetronidazole inhibited B. fragilis growth in vitro [309]
Aerobic vaginitis
Chlorhexidine
Chitosan-based vaginal inserts increased the
antimicrobial activity against E. coli of
chlorhexidine in vitro
[307]
Chitosan-based vaginal inserts increased the
antimicrobial activity against E. coli of
chlorhexidine in vitro
[308]
Metronidazole Metronidazole vaginal tablets containing chitosanexhibited in vitro antimicrobial effect against E. coli [310]
Trichomoniasis
-
In vitro antimicrobial effect was related to the




Increased in vitro antimicrobial activity of
chitosan-coated NPs compared to noncoated [270]
Antimicrobial effect of metronidazole was
maintained when in chitosan delivery system [311]
- The hydrogel containing chitosan proved to reduceT. vaginalis motility in biological fluids [312]
Vaginal gel
Candidiasis
- Chitosan hydrogel was confirmed to have intrinsicantifungal properties in vitro [313]
Thymbra capitata
essential oil
Chitosan hydrogel with essential oil showed
increased in vitro antifungal activity and the ability




Chitosan hydrogel with the extract obtained





Superior in vitro antifungal activity by LMW




containing essential oil expressed antifungal
activity in vitro
[317]
- Chitosan hydrogel significantly reduced biofilmformations both in vitro and in an in vivo model [318]
Iminoboronate
Fungicidal activity in biomimetic conditions and





Low concentration chitosan hydrogel efficiently
eradicated Pseudomonas aeruginosa biofilms in vitro [24]
Superior in vitro activity against S. aureus and
S. epidermidis by chitosan formulated as hydrogel [8]
Metronidazole
3D printed vaginal ring containing chitosan and
metronidazole obtained a bactericidal effect against
E. coli and confirmed synergistic antibacterial effect
by chitosan and metronidazole
[320]
Trichomoniasis Auranofin
The chitosan-based hydrogel containing auranofin
NPs managed to completely inhibit parasite
growth in vitro in a dose-dependent manner
[321]





Infection Active Ingredient Main Finding(s) Ref.
Chlamydia Resveratrol
Superior antichlamydial activity in vitro was by






The chitosan-based vaginal film obtained in vitro




Drug-free chitosan vaginal film expressed in vitro
fungicidal activity; however, superior activity when
loaded with tioconazole
[323]
Econazole Chitosan-based matrices containing econazolemicroparticles expressed antifungal activity in vitro [324]
Bacterial vaginosis Metronidazole
Chitosan-based membrane did not restrain the effect
of metronidazole against S. aureus and G. vaginalis
in vitro
[325]
Aerobic vaginitis Ciprofloxacin Vaginal films enhanced the activity of ciprofloxacinagainst E. coli and S. aureus in vitro [326]
CNPs: chitosan nanoparticles, NPs: nanoparticles, PIBCA: poly(isobutylcyanoacrylate), LMW: low molecular weight, MPs: microparticles.
5.3.1. Particles and Carriers
Chitosan nanoparticles (CNPs) were also tested for vaginal administration. Recent
work by Facchinatto and colleagues explored CNPs containing clotrimazole, a widely used
antifungal drug, for the localized treatment of vulvovaginal candidiasis [285]. Cationic
N-(2-hydroxy)-propyl-3-trimethylammonium, O-palmitoyl CNPs were evaluated for an-
ticandidal activity. The activity of clotrimazole decreased when associated with CNPs,
with an increase in MIC values. However, the in vitro safety profile was improved when
clotrimazole was loaded into CNPs, and the prolonged release was achieved [285].
Many natural substances show promise as alternatives to antibiotics in treating in-
fections. Arumugam and Rajendran incorporated Callophycin A, a seaweed-derived
metabolite, into CNPs and studied in vitro and in vivo anticandidal effects [286]. Callo-
phycin A-loaded CNPs showed significant anticandidal activity both in vitro and in the
vulvovaginal candidiasis animal model after six days of treatment. The CNPs alone did
not exhibit antifungal activity; however, a synergetic effect between Callophycin A and
CNPs was determined [286].
Murine vulvovaginal candidiasis model was also applied in a study on the antican-
didal effect of thiosemicarbazide encapsulated in CNPs [287]. Thiosemicarbazide is a
compound with an antifungal effect, but its biological effect is reduced due to in vivo
degradation. The CNP-associated thiosemicarbazide obtained a noticeable reduction in the
fungal burden after seven days of treatment, suggesting a synergistic effect [287]. CNPs
alone did not affect the fungal burden.
Intravaginal application of miconazole nitrate is widely used as a treatment of vulvo-
vaginal candidiasis. Novel delivery systems can enable an antifungal activity with lower
drug concentration and dosing frequency, resulting in reduced side effects. CNPs for
miconazole delivery, targeting vulvovaginal candidiasis, was studied in vivo by Amaral
and colleagues [288]. The C. albicans-infected mice received treatment for seven days,
and the antifungal effect of CNPs containing miconazole was compared to conventional
miconazole cream. Both formulations showed a significant antifungal burden, and the
CNPs containing a seven-fold lower drug concentration than the cream obtained a similar
therapeutic effect [288].
The combination of available antifungal compounds and natural substances can
enable an enhanced activity of existing drugs. Farnesol is found in plant extracts and
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has shown effectiveness against several microbials, including the antifungal effect. CNPs
containing miconazole or farnesol have been assessed for their anticandidal activity to
explore the possible adjuvant effect of farnesol [289]. Both in vitro and murine vulvovaginal
candidiasis models were employed. The in vitro susceptibility test weakened the theory
of the synergistic effect of miconazole and farnesol, with no enhanced effect by including
farnesol in the formulation. In vivo results showed that the combination of miconazole
and farnesol in CNPs was the most effective treatment; however, not significantly better
compared to miconazole CNPs [289].
Electrospraying as a production technique to generate CMPs and CNPs is gaining
attention. Moreno et al. developed chitosan microcapsules containing dry extracts of
Argentinean medicinal plants through electrospraying, targeting the localized treatment of
vulvovaginal candidiasis [290]. Argentinean medicinal plants have been shown to possess
biological properties. These properties were maintained when encapsulated in chitosan
microcapsules, and a strong antifungal capacity was obtained in the in vitro C. albicans
challenge [290].
Doxycycline is a widely used antibiotic for various vaginal infections, including
bacterial vaginosis, chlamydia and mycoplasma. Cover et al. studied the antibacterial
activity of doxycycline-loaded CNPs and explored the synergy of drug and polymer [291].
CNPs containing doxycycline expressed a significant reduction in the viability of E. coli
in vitro. The CNPs alone did not inhibit the bacterial growth; however, the cytotoxicity
related to free doxycycline was significantly reduced when entrapped in CNPs, suggesting
a prominent role of chitosan in improving the biocompatibility of drugs [291].
Microscale chitosan particles have also been assessed as carriers with the potential
in localized treatment of vaginal infections. Cirri et al. developed chitosan and chitosan-
alginate microspheres containing metronidazole for vaginal administration [265]. Antibi-
otic metronidazole is commonly used to treat bacterial vaginosis, generally administered
orally, causing several side effects. Hence, the appropriate formulation for local administra-
tion could improve the therapy considerably. Chitosan–alginate microspheres expressed
superior growth inhibition of B. fragilis in vitro compared with chitosan microspheres [265].
The same group previously evaluated the antibacterial effect of chitosan–alginate
microspheres containing antibiotic cefixime, used in the treatment of various infections,
including aerobic vaginitis and gonorrhoea. Cefixime microspheres had the ability to
reduce the E. coli viability to the same extent as a free drug, suggesting improved effect
due to the improved mucoadhesive ability of the system [292].
In recent years, also fungal chitosan has gained increased attention. Chitosan with
beneficial properties for healthcare applications can be obtained from fungi, as an alterna-
tive to the commonly used marine source [21]. Elmi et al. developed CNPs with chitosan
obtained from Penicillium fungi and evaluated their in vitro antimicrobial effect against
T. vaginalis [293]. Compared with the antimicrobial drug metronidazole, applied as positive
control, the effectiveness of CNPs was dependent on the polymer concentration and dura-
tion of the exposure. Nevertheless, CNPs significantly eliminated the T. vaginalis burden
in vitro [293].
N. gonorrhoeae is the second most common bacterial STI, and the available treatment
options are continuously reduced due to the AMR development [10]. Alqahtani et al.
formulated CNPs and evaluated their antibacterial effect against various N. gonorrhoeae
strains in vitro, including strains sensitive to conventional antibiotics and multidrug-
resistant strains [294]. The developed CNPs expressed antibacterial effect against all
tested strains, confirming the therapeutic potential of CNPs also for high-level resistant
N. gonorrhoeae [294].
5.3.2. Coating Material and Excipients
The application of chitosan as a component in vaginal drug delivery systems is versa-
tile and entails many opportunities and advantages [75]. Surface modification of NPs can
provide the necessary properties to improve topical therapy, and the use of chitosan as a
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coating material is a widely known approach for generating mucoadhesive NPs suitable
for vaginal formulations. Calvo et al. designed chitosan-coated nanocapsules as carri-
ers for azole antifungals tioconazole and econazole [295]. Chitosan-coated nanocapsules
maintained the antifungal activity against C. albicans for both drugs in vitro. Unloaded
nanocapsules and chitosan on their own did not express anticandidal activity [295]. In
another study, the surface of PLGA NPs was modified with chitosan to obtain mucoadhe-
sive properties [296]. Clotrimazole was loaded into the PLGA NPs and challenged against
C. albicans, comparing the activity of chitosan-coated and noncoated NPs containing drug
to the free drug. Chitosan-coated PLGA NPs showed superior anticandidal activity in vitro
and increased the effectiveness of clotrimazole [296].
Andersen et al. developed a chitosan-based delivery system with chitosan both
entrapped in liposomes and available on the liposomal surface as a coating layer [27]. The
chitosan-based formulation containing metronidazole and the drug-free formulation were
challenged against C. albicans in vitro. A superior antifungal activity was observed for the
chitosan formulations compared to free drug, plain liposomes, and Carbopol-containing
liposomes. Moreover, the inhibition of C. albicans was equal for the chitosan-based delivery
system containing metronidazole and the drug-free formulation, confirming the intrinsic
antifungal properties of chitosan [27].
Recently, microemulsion associated with chitosan was also assessed for its potential in
the topical treatment of vulvovaginal candidiasis [297]. Both chitosan and herbal medicine,
Stryphnodendron adstringens extract, Melaleuca alternifolia essential oil and tea tree oil, was
incorporated in the microemulsion, replacing the aqueous phase. All constituents of the
microemulsion expressed C. albicans activity in vitro; however, compounds were tested sep-
arately, and the effect of formulation needs to be further evaluated to confirm the favourable
influence of the chitosan delivery system in vulvovaginal candidiasis treatment [297].
Metronidazole is primarily applied in treating bacterial vaginosis; however, it often
fails to eradicate possible coinfection by Candida spp. The combination of metronidazole
and chitosan can obtain an effective treatment of such coinfection due to the inherent anti-
fungal properties of chitosan. Perinelli et al. prepared metronidazole-associated chitosan,
either as free polymer or CNPs, added to hydroxypropylmethyl cellulose hydrogel [298].
Anticandidal activity in vitro was assessed and compared to free metronidazole in solution
or hydrogel, and the antimicrobial activity was increased in the presence of chitosan. How-
ever, the presence of the drug in formulations containing chitosan as free polymer or as
CNPs did not increase the antimicrobial activity against tested Candida spp. strains. Thus,
proving that metronidazole did not influence the intrinsic antifungal effect of chitosan [298].
In another study, chitosan-based microplatelets was developed for the intravaginal
delivery of amphotericin B deoxycholate, aiming at localized therapy of vulvovaginal
candidiasis [299]. The chitosan microplatelets containing amphotericin B were dispersed
in Pluronic® F127 hydrogel, and the antifungal activity against C. albicans was assessed
both in vitro and in vivo. The optimized formulation obtained a complete infection cure
in the murine vulvovaginal candidiasis model. The in vitro evaluation corroborated these
findings. Moreover, the chitosan-based microplatelets exhibited synergistic activity with
associated amphotericin B in the in vitro antifungal evaluation [299].
Chitosan can interact with other polymers, forming complexes with beneficial proper-
ties. Darwesh et al. evaluated the anticandidal effect of chitosan and anion–polyelectrolyte
complex vaginal inserts for the localized delivery of antifungal drug fluconazole [300]. The
antifungal effect was assessed both in vitro and in the vulvovaginal candidiasis animal
model. Fluconazole vaginal insert showed improved antifungal activity both in vitro and
in vivo compared with the free drug [300].
Natural origin substances, as alternatives to existing antimicrobials, strengthen the
potential of improved and successful therapy of complicated and recurrent infections.
Natural molecule curcumin has shown to possess various beneficial properties, includ-
ing anti-inflammatory and antifungal. Salmazi et al. aimed to exploit these properties
by loading curcumin into liquid crystal precursor mucoadhesive system containing chi-
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tosan targeting vulvovaginal candidiasis [301]. While the delivery system did not inhibit
C. albicans growth on its own, the curcumin-loaded liquid crystalline formulations ex-
pressed anti-candida activity in vitro. Moreover, the antifungal effect was considerably
more potent when curcumin was associated with formulation than free curcumin [301].
Subsequently, a similar system of liquid crystalline containing chitosan for the vaginal
delivery of curcumin was assessed for its antifungal activity in vivo and in vitro, as well
as on C. albicans biofilm [302]. The optimized formulation was shown to improve the
antifungal potency of curcumin in vitro, and activity was seen when challenged against
fluconazole-resistant strains. The fungal burden in the murine vulvovaginal candidiasis
model was significantly decreased by the formulation after four days of treatment, corrobo-
rating the in vitro findings. Moreover, the optimized formulations efficiently reduced the
in vitro growth of biofilm, obtained using clinical strains [302].
The use of chitosan as an excipient in vaginal tablets can provide the mucoadhe-
sive properties necessary to achieve successful localized therapy. Fitaihi et al. developed
chitosan-based vaginal tablets containing fluconazole for vulvovaginal candidiasis treat-
ment [303]. The tablet formulation increased the antifungal activity of fluconazole against
C. albicans with a greater inhibition zone compared with the free drug [303]. Chitosan-
based vaginal tablets have also been explored as a delivery system for the natural active
ingredient, namely Chelidonii herba lyophilized extract [304]. The chitosan-based tablets
containing extract were challenged against various Staphylococcus spp., P. aeruginosa, and
C. albicans to evaluate their in vitro antimicrobial activity. However, the tablet formulation
detained the activity of Chelidonii herba extract, and a superior effect was obtained by the
free extract [304].
A novel approach for improved treatment of vaginal candidiasis is the in situ vaginal
gel containing gel flakes. Gel flakes have a thin threadlike shape with polygonal structures.
Abd Ellah et al. developed gel flakes containing antifungal drug ketoconazole via gelation
of gellan gum solution containing drug mixture (ketoconazole /β-cyclodextrin) in the
presence of chitosan, forming the chitosan and gellan gum gel flakes [305]. The gel flakes
containing ketoconazole were further incorporated into in situ thermosensitive gel, and
the formulation was assessed for in vitro and in vivo antifungal activity. In vitro anti-
candida activity of the formulation was compared to free ketoconazole and marketed
terconazole vaginal cream, and the inhibition zone after 48 h was significantly better for
the gel flakes formulation. In a pilot study involving 100 vulvovaginal candidiasis patients,
the efficacy of ketoconazole gel flakes formulation was equivalent to the marketed product,
confirming the in vivo effect of the novel system [305]. A similar approach was developed
by Permana et al. comprising thermosensitive in situ vaginal gel combined with the gel-
flake system of itraconazole-containing solid dispersion powder [306]. In vivo antifungal
activity was evaluated using a vulvovaginal candidiasis animal model. It was found that
the combination of the solid dispersion, gel-flakes, and in situ gel significantly improved
the anticandidal effect of itraconazole [306].
Vaginal inserts based on chitosan complexes have been studied for the delivery of
other antibiotics as well. Chitosan and alginate complex for vaginal delivery of chlorhexi-
dine was evaluated for its antimicrobial activity towards both C. albicans and E. coli [307].
Vaginal inserts increased the antimicrobial activity of chlorhexidine in vitro after 24 h of
incubation [307]. Subsequent studies by the same group explored the antimicrobial activity
of chlorhexidine in a similar delivery system. Vaginal inserts based on chitosan and car-
boxymethylcellulose complexes containing chlorhexidine was challenged against the same
pathogens [308]. Results aligned with earlier findings suggesting the future applicability of
vaginal inserts against vaginal infections, such as candidiasis and aerobic vaginitis.
Staphylococcus spp. is naturally found on mucosal surfaces, and to explore the antibac-
terial effect of chitosan, Jøraholmen et al. challenged chitosan-coated liposomes against
methicillin-resistant or sensitive strains of S. aureus and S. epidermidis [8]. The activity of
chitosan-based formulations (free of drug) was compared to noncoated liposomes (free
of chitosan) and antibiotic vancomycin. The chitosan-coated liposomes expressed an an-
Mar. Drugs 2021, 19, 697 31 of 53
tibacterial effect against S. epidermidis in all tested concentrations, while merely the highest
chitosan concentration showed activity against S. aureus. Noncoated liposomes did not
show any antibacterial impact, confirming the antimicrobial properties of chitosan [8].
In another study targeting bacterial vaginosis, Perioli et al. prepared mucoadhesive
vaginal tablets containing chitosan, as well as antibiotic metronidazole, and tested their
ability to inhibit B. fragilis growth in vitro [309]. Tablets with various ratios of chitosan and
other polymers were assessed, and superior antibacterial inhibition was seen in the 1:1
chitosan and PVP tablets [309].
Metronidazole vaginal tablets comprising chitosan were also developed by Lupo
and colleagues [310]. Synthesized S-protected chitosan was added as a mucoadhesive
excipient, and to assess the potential in localized treatment of aerobic vaginitis, their ability
to inhibit E. coli in vitro was measured. Vaginal tablets with S-protected chitosan exhibited
antimicrobial effect; however, with a reduced growth inhibition zone compared to that of
free metronidazole and metronidazole released from unmodified chitosan, possibly due to
the prolonged release from the vaginal tablets [310].
Another study on the antimicrobial effect of chitosan, excluding the influence of
the antibiotic drug, was performed by Pradines et al., who produced chitosan-coated
poly(isobutyl cyanoacrylate) (PIBCA) NPs [271]. Their findings suggested that the in vitro
antimicrobial effect against T. vaginalis was related to the PIBCA NPs, however, merely
when the NPs were chitosan-coated [271]. The same group evaluated the activity against
T. vaginalis using the same chitosan-coated NPs containing the antibiotic drug metron-
idazole [270]. Chitosan as a pharmaceutically active ingredient was confirmed, and its
activity might be due to morphological changes of T. vaginalis caused by the chitosan-
coated NPs [270]. In another study, metronidazole-associated chitosan was added to a
thermosensitive Pluronic® F127 hydrogel aiming for topical therapy of vaginal trichomo-
niasis infection [311]. The effect of free drug metronidazole in the formulation, as well as
drug-free formulation, were assessed for their antimicrobial activity against T. vaginalis
in vitro. The antimicrobial effect of metronidazole was maintained in hydrogel formula-
tion, in contrast to the action of metronidazole in solution. Drug-free hydrogel decreased
the T. vaginalis viability as well; however, high concentrations of chitosan was required,
confirming the intrinsic antimicrobial activity of chitosan [311]. T. vaginalis motility in
biological fluids is an important quality in the infectivity of the parasites. Subsequent
studies aimed to evaluate the effect on T. vaginalis motility [312]. A similar thermosensitive
hydrogel containing chitosan was used, except no drug was added to the formulation.
The hydrogel containing chitosan was able to reduce T. vaginalis motility in biological
fluids; however, Pluronic® F127 hydrogel free of chitosan more efficiently immobilized the
parasites, enabling prevention of infection [312].
5.3.3. Polymer-Based Vaginal Gels
Semisolid formulations in the form of vaginal gels are one of the most extensively
investigated vaginal dosage forms [282]. In particular, polymer-based hydrogels are known
as a promising strategy to achieve improved localized therapy of vaginal infections [262].
Numerous studies have been conducted evaluating chitosan hydrogel as an excipient in
pharmaceutical formulations, a carrier of pharmacological substances, a secondary vehicle
for particulate delivery systems, and an intrinsic antimicrobial aiming for the localized
therapy of vaginal infections [74].
Chitosan hydrogel is proven to own intrinsic antimicrobial properties. The potential
of chitosan hydrogel as treatment of vulvovaginal candidiasis was evaluated, and drug-
free hydrogel was challenged against a wide range of Candida spp. in vitro. Results
demonstrated the varying potency against the different Candida strains; however, they
confirmed the intrinsic antifungal properties of chitosan hydrogel [313]. The antimicrobial
action was suggested to be caused by membrane damage due to the interaction between
the protonated amino groups of chitosan and the negatively charged membrane proteins of
Candida spp. This theory is supported for other formulations of chitosan as well [26]. The
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choice of active ingredient can influence the antimicrobial activity of chitosan hydrogel, and
Palmeira-de-Oliveira et al. tested the possible synergistic effect of Thymbra capitata essential
oil and chitosan [314]. In vitro antifungal evaluation confirmed an increased activity by
chitosan hydrogel associated with Thymbra capitata essential oil. Moreover, the formulation
was able to disrupt the Candida biofilm in a dose-dependent manner [314]. In another study,
methanolic extract of Mitracarpus frigidus was incorporated into chitosan hydrogel [315].
The murine vulvovaginal candidiasis model was used to evaluate the in vivo antifungal
activity, and the activity of chitosan hydrogel containing extract was compared to the
marketed product of antifungal clotrimazole cream. The Mitracarpus frigidus chitosan
hydrogel expressed a superior antifungal effect after three days of treatment and an equal
impact after six days of treatment, compared to the marketed product [315].
The antimicrobial properties of chitosan hydrogels can be influenced by the MW, DDA,
ionic strength, and pH [74]. Şenyiğit et al. studied chitosan hydrogels of LMW, MMW, and
HMW containing the antibiotic drug, miconazole, or econazole, for their in vitro antifungal
effect [316]. C. albicans inhibition was superior; nevertheless, authors suggested MMW
hydrogel as superior for the topical therapy of vulvovaginal candidiasis due to favourable
mucoadhesive, mechanical, and release properties. Unexpectedly, chitosan hydrogel on its
own did not express any inhibition of fungal growth [316].
The use of nanosystems can increase the potency of incorporated active ingredients,
both conventional antibiotics and natural substances, and in combination with mucoadhe-
sive chitosan hydrogel, the localized treatment of vaginal infections can be improved. Dos
Santos et al. combined the nanoemulsion containing Pelargonium graveolens essential oil
with chitosan hydrogel aiming to optimize the activity for the successful treatment of vul-
vovaginal candidiasis [317]. Nanoemulsions, with and without essential oil, and chitosan
hydrogel with and without the nanoemulsions containing essential oil were challenged
against various Candida spp. in vitro. The chitosan hydrogel on its own expressed antifun-
gal activity against several strains and was found superior to the nanoemulsion containing
essential oil for most strains. Moreover, the chitosan hydrogel-thickened nanoemulsion
containing P. graveolens essential oil showed a significant reduction in MIC compared to
plain essential oil [317].
Persistent bacterial biofilms might be a contributing factor to recurrent infections and
the failure to completely eradicate both vulvovaginal candidiasis and bacterial vaginosis.
Silva-Dias et al. used a mouse subcutaneous foreign body system to evaluate the effect
of chitosan hydrogel on Candida biofilm [318]. The efficacy of chitosan was confirmed by
significantly reduced biofilm formations both in vitro and in vivo and its ability to disrupt
a preformed biofilm [318]. In another study, iminoboronate-chitosan hydrogels were
prepared using 2-formylphenylboronic acid as crosslinking agent [319]. Hydrogels were
evaluated regarding antibiofilm and fungicidal activity. Iminoboronate-chitosan hydrogels
inhibited the formation of Candida biofilms in vitro and reduced their metabolic activity by
more than 99.5%. Moreover, an efficient fungicidal activity in biomimetic conditions was
obtained [319].
The ability of chitosan hydrogel to act on biofilm was confirmed against bacterial
vaginosis-associated biofilm as well. Kandimalla et al. found that low concentration
chitosan hydrogel effectively eradicated P. aeruginosa biofilms in vitro [24].
The chitosan-based hydrogel can also be used as a secondary vehicle, incorporat-
ing nanocarriers. Jøraholmen et al. developed liposomes-in-hydrogel to evaluate the
intrinsic antibacterial properties of chitosan by assessing the in vitro activity against
Staphylococcus spp. [8]. Various concentrations of chitosan hydrogel containing drug-free
liposomes were tested against methicillin-resistant or sensitive strains of S. aureus and
S. epidermidis. Antibacterial activity against all tested strains was demonstrated for all chi-
tosan concentrations. In this study, the effect of formulation on the antibacterial properties
of chitosan was assessed. As mentioned in the section on excipients, chitosan-coated lipo-
somes inhibited the growth of S. epidermidis in all concentrations; however, S. aureus was
merely inhibited by the higher chitosan concentration (0.3%). These findings suggest the
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superiority of chitosan formulated as hydrogel and that the antibacterial effect of chitosan
is dependent on bacteria as well as the type of formulation [8].
In a recent study, vaginal rings were manufactured using 3D printing [320]. The
vaginal rings were filled with polymer-based gels containing antibiotic metronidazole, and
their effect was evaluated in vitro against C. albicans and E. coli. The empty vaginal ring,
metronidazole-containing vaginal ring, chitosan and hydroxyethyl cellulose-containing
vaginal ring, and chitosan and metronidazole-containing vaginal ring were included in
microbiological evaluation over 24 h. The effect against C. albicans was initially superior
for the chitosan and metronidazole-containing vaginal ring; however, after eight hours, the
fungal growth was similar to the untreated controls. In the E. coli challenge, all preparations
expressed an antibacterial effect. The vaginal ring containing chitosan and metronidazole
obtained a bactericidal effect after 24 h and was found superior. The findings confirmed a
synergistic effect of chitosan and metronidazole against E. coli [320].
The antirheumatic drug, auranofin, exhibits significant trichomonacidal activity in
low concentrations both in vitro and in vivo in a murine infection model [327]. To avoid
simultaneous adverse effects and exploit the beneficial properties of auranofin in topical
therapy of trichomoniasis, Zhang et al. incorporated the drug into PLGA NPs [321]. NPs
were subsequently incorporated into a β-glycerophosphate and chitosan-based thermosen-
sitive hydrogel and challenged against T. vaginalis in vitro. Although the auranofin NPs in
the hydrogel formulation was less potent than the free drug, the formulation managed to
completely inhibit parasite growth in a dose-dependent manner. Drug-free formulation
did not influence the T. vaginalis growth [321].
The combination of two delivery systems, a drug nanocarrier incorporated into a
chitosan hydrogel, has recently been evaluated for its antibacterial effect, namely the
liposome-in-hydrogel delivery system. Jøraholmen et al. aimed to prove the in vitro an-
tichlamydial effect of natural substance resveratrol in a suitable delivery system [276].
C. trachomatis infected cells were exposed to free resveratrol, liposomal resveratrol, resver-
atrol liposomes-in-hydrogel and respective controls free of resveratrol. All resveratrol
formulations reduced the number of infected cells, and compared with free resveratrol,
a superior antichlamydial activity was seen for resveratrol liposomes-in-hydrogel in the
lower concentrations. The intracellular bacteria were not affected by the chitosan-based
hydrogel free of resveratrol [276].
5.3.4. Vaginal Films
Vaginal films are considered solid dosage forms and are usually thin, soft, and flex-
ible and disperse or dissolve in contact with vaginal fluids. Films are formulated using
polymers, either one or a combination of polymers, and due to its mucoadhesive and an-
timicrobial properties, chitosan is highly suitable for vaginal film preparation [282]. Mishra
et al. prepared a mucoadhesive vaginal film containing fluconazole by using polymers
chitosan and pectin with glycerol as plasticizer [322]. To assess the antifungal activity,
the optimized vaginal film was challenged against C. albicans in vitro. Moreover, the
Lactobacillus inhibition was studied to exclude adverse effects on vaginal flora. Compared
with a marketed gel containing fluconazole, the chitosan-based vaginal film obtained a
similar C. albicans growth inhibition. Moreover, the optimized vaginal film did not suppress
the growth of Lactobacillus, and no significant difference was seen in growth inhibition
compared to the marketed product [322].
Tioconazole has been shown to hold higher activity against C. albicans compared
with some of the commonly applied azole antifungals. Calvo et al. prepared vaginal
chitosan-based films containing tioconazole, with chitosan and a combination of chitosan
and hydroxypropyl methylcellulose [323]. The in vitro biological activity of drug-free
films and films loaded with tioconazole was evaluated over time against C. albicans and
compared to tioconazole vaginal capsules. A superior and more rapid anticandidal effect
was observed for the vaginal films than both capsules and free drug in the 96-h assay. The
inhibition zone for the tioconazole vaginal capsules was reduced by 89% after 96 h. Two
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hours into the study, a similar reduction for the vaginal films was 24–41%, indicating the
beneficial sustained drug release from the beneficial sustained drug release films. The
highest C. albicans inhibition was seen for the vaginal film developed with chitosan as the
only polymer loaded with tioconazole. Moreover, drug-free chitosan vaginal film presented
fungicidal activity [323].
In a different approach, an econazole vaginal delivery system comprising chitosan
and poloxamer matrix containing drug-loaded Eudragit MPs was developed [324]. The
in vitro antifungal activity of chitosan-based matrices with econazole MPs was compared
to the activity of matrix with unloaded MPs and merely matrix. All matrices containing
econazole produced an equally sized C. albicans inhibition zone, while no inhibition was
seen for the drug-free formulations [324].
Tentor et al. developed the chitosan-based membrane for vaginal application as a
potential formulation for the management of bacterial vaginosis [325]. The membrane was
prepared by allowing the dried alginate hydrogel containing metronidazole to swell in
chitosan solution. Chitosan penetrates the alginate dry film, forming the membrane. The
in vitro antimicrobial activity of drug-loaded membranes was evaluated against S. aureus
and G. vaginalis and compared to the action of drug-free membrane and free metronidazole.
The chitosan-based membrane did not restrain the antimicrobial effect of metronidazole
and expressed equal activity against both strains compared to the free drug [325].
In another study, chitosan on its own and chitosan and poly(2-ethyl-2-oxazoline)
was used to develop vaginal films [326]. The in vitro antibacterial activity was evaluated
against E. coli and S. aureus, comparing the effect of drug-free films and films loaded with
ciprofloxacin. The drug-free films did not express antibacterial activity against S. aureus;
however, the film with a combination of polymers expressed some activity against E. coli.
Moreover, the vaginal films containing ciprofloxacin enhanced the action of the drug, with
superior growth inhibition against both bacteria compared with the free drug [326].
6. Other Localized Antimicrobial Therapies
6.1. Ocular Infections
Ocular bacterial infections, including keratitis, conjunctivitis, blepharitis, endoph-
thalmitis, dacryocystitis, and orbital cellulitis, are exciting targets to explore the extended
role of chitosan as an active pharmaceutical ingredient. Common causes of infections
comprise S. aureus, coagulase-negative Staphylococcus, P. aeruginosa, Streptococcus pneumonia,
E. coli, and Serratia species [328]. However, successful localized therapy is highly dependent
on the performance of the drug vehicle–delivery system. It is well established that the
ocular site represents one of the most challenging mucosal sites; the corneal penetration
is extremely limited (up to 5%) due to eye reflection, blinking, and tear fluid turnover. In
addition, a very limited volume of the formulation can be instilled to the eye [329,330].
The cornea, the anterior eye region of the eye, is comprised of the epithelium, stroma,
and endothelium. It serves as a mechanical barrier for the drug delivery systems. Due
to the cornea´s superficial layers, the lipophilic epithelium, and the hydrophilic stroma,
the permeation of different active ingredients is highly reduced [331]. The presence of
high lipid content in the epithelium and endothelium limits the passage of hydrophilic
molecules [332]. Rapid elimination, poor bioavailability, on-site irritations, accompanied
by low patients’ compliance, limit the success of localized ocular delivery [333]. To as-
sure a sufficient residence time at the site of infection, the mucoadhesiveness combined
with intrinsic antimicrobial activity make chitosan highly relevant for the treatment of
ocular infections.
Chitosan and its derivatives have been widely studied as a building block for various
advanced drug delivery systems destined for ocular administration [333]. Moreover,
chemical modifications have been introduced to enhance its mucoadhesiveness. Among
ocular infections, widely prevalent bacterial conjunctivitis affecting patients of all ages is
one of the common targets. Clarithromycin-loaded CNPs were shown to be effective in
managing bacterial conjunctivitis due to increased precorneal residence time [334].
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Chitosan was often studied in combination with other pharmaceutical excipients; for
example, chitosan/cyclodextrin nanospheres were evaluated in vitro for their potential to
improve the delivery of levofloxacin, a third-generation tricyclic quinolone. Novel NPs
exhibited 2-fold increased antibacterial activity against both Gram-positive and Gram-
negative bacteria compared with the free drug [328]. Sustained release of levofloxacin was
also achieved utilizing thermosensitive chitosan-based hydrogel targeting postoperative
endophthalmitis. The aim was to assure the drug´s release for at least seven days after a
single instillation post cataract surgery [29].
Mirzaeei and colleagues proposed nanofibers comprising PVA/chitosan single-layered
as well as PVA/chitosan/Eudragit RL100 multilayered electrospun nanofibers as a superior
vehicle for ocular delivery of antibiotic ofloxacin. Animal studies revealed that nanofibers
effectively retained the drug concentration in the tear fluid of rabbits above the MIC90%
for up to 95 h [335].
Infectious keratitis is characterized by a concurrent infection and inflammation of the
cornea that, if untreated, can cause the destruction of the cornea. Bacterial keratitis is mainly
caused by P. aeruginosa and S. aureus; however, the infection can also be caused by fungi,
parasites, or viruses. CNPs were evaluated as a superior delivery system for tobramycin
sulphate in vitro and ex vivo conditions and showed improved performance [336].
Novel delivery systems offer the possibility to simultaneously deliver anti-infective
and anti-inflammatory drugs, such as chitosan and chitosan derivates-based nanocarriers
bearing dexamethasone sodium phosphate and chloramphenicol proposed by Karava
et al. [330]. The derivatives improved both the mucoadhesive properties and antimicrobial
activity against S. aureus and E. coli. Gade et al. prepared a drug-eluting polymeric contact
lens for the effective delivery of moxifloxacin and dexamethasone. The drug-loaded
contact lens exhibited significantly greater corneal drug distribution and superior in vitro
and in vivo antimicrobial activity compared with the standard formulation, suggesting
broader applicability in the prevention of postoperative ocular infections [329].
Fungal keratitis (keratomycosis) is an ocular infection comprising corneal inflamma-
tion [337]. It is caused by filamentous fungi such as Aspergillus flavus, A. fumigatus and
Candida. Its incidence and frequency are alarmingly increasing due to the increased use of
contact lenses and the number of immunocompromised patients [331,333]. Luliconazole,
an imidazole antifungal drug, was successfully incorporated in chitosan-based NPs with
superior residence time and improved ocular tolerance as a novel formulation to treat
fungal keratitis [333]. Voriconazole, a second-generation antifungal, was incorporated in
mucoadhesive (chitosan-coated) cubosome and challenged in a rabbit model. The novel
chitosan-coated cubosomes significantly improved transcorneal permeation and ocular
residence [331].
Verma and colleagues developed trimethyl chitosan-coated niosomes for natamycin,
with improved mucoadhesive properties, drug release profile, and limited irritancy. Trimethyl
chitosan improved the paracellular permeability of the epithelial barrier present at the
ocular surface. The novel system exhibited improved natamycin PK/PD in the rabbit
model [337].
6.2. Buccal Treatment
The oral cavity has been highlighted as a site for bioadhesive drug delivery for a
long time [338]. It is highly suitable for local drug delivery into the oral cavity target-
ing toothaches, fungal infections, gingivitis, mucosal lesions, and periodontitis. Those
conditions are particularly challenging to treat among pediatric patients [339]. Utilizing
mucoadhesiveness of chitosan to prolong formulations´ residence within the buccal cavity
has been explored for a variety of chitosan-based delivery systems.
Among commonly studied delivery systems, mucoadhesive buccal films gained
attention due to their superior palatability. The antifungal multilayer system composed of
cationic chitosan and anionic pectin was developed for controlled delivery of clotrimazole
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by Potas et al. [340]. Chitosan improved the antifungal activity of the drug, indicating the
system´s potential in the treatment of resistant oral candidiasis.
The monolayer and bilayered mucoadhesive film and wafer formulations comprising
chitosan and hydroxypropyl methylcellulose (HPMC) were developed by Timur et al. to
deliver cefuroxime axetil [341]. Chitosan enhanced the antimicrobial activity, while its
penetration enhancing property assisted a penetration of the drug into deeper layers of
the oral tissues. Abou Hussein and colleagues studied chitosan blended with PVA-based
buccal film as a vehicle for cetylpyridinium chloride, a quaternary pyridinium antiseptic,
confirming its superior antimicrobial activity and good kill-time against Streptococcus
mutants [339].
A clear and relatively unexplored potential of chitosan as an intrinsic antimicrobial
has been recently confirmed by Li et al., who showed the inherent antibacterial activity
of chitosan scaffolds alone for the first time [342]. The noncrosslinked chitosan scaffold
was challenged against typical oral pathogens, Gram-negative Porphyromonas gingivalis,
and Gram-positive S. mutans. Both pathogens were killed at six hours. Interestingly,
β-glycerophosphate crosslinked scaffolds showed no antibacterial activity. The findings
suggest that the noncrosslinked chitosan scaffolds offer both antimicrobials as well as
wound healing potential. Considering that they are drug-free, their suitability in localized
antimicrobial therapy is even more important [342].
Oropharyngeal candidiasis is one of the most prevalent fungal infections [343]. The au-
thors prepared the polyelectrolyte films of chitosan-gum-arabic and chitosan-polygalacturonic
acid loaded with nystatin. Both formulations exhibited significant antifungal activity. In-
terestingly, a minor effect was seen in the placebo formulation comprising only chitosan
and gum arabic. Still, no antimicrobial effect was found in the placebo (drug-free) films
containing polygalacturonic acid. Polymeric films comprising chitosan, carbopol, gelatin,
gum arabic, and alginate were used to prepare the polymeric matrices for miconazole
nitrate. The antifungal challenge against the five most important fungal opportunistic
pathogens of the Candida genus revealed that the chitosan-gelatin and chitosan-carbopol
matrices exhibited superior in vitro activity [344]. Interestingly, chitosan alone showed
antifungal activity. The mucoadhesive sponges containing a mixture of tenoxicam and
miconazole nitrate were prepared to target recurrent aphthous ulcer, an inflammatory
disease accompanied by a candida infection. Medicated chitosan (2%) sponges caused a
significant decrease in the acetic acid-induced ulcer size in rats after six days of treatment
compared with negative and positive controls. Additionally, histopathological examination
showed faster healing with complete restoration of the normal oral histology in rats [345].
Recently, awareness has been raised regarding the formation of biofilms on dental and
mucosal surfaces. Effective eradication of biofilms with antimicrobials requires both a high
concentration and long exposure time. The miniaturized drug delivery devices, known
as microcontainers, able to deliver the antimicrobial peptide nisin to an oral multi-species
biofilm were proposed by Birk et al. [346]. The antibacterial effects of novel microcontainers
exhibited a faster onset (after three hours) than solution-based delivery (after nine hours).
Mucositis, an oral inflammation with painful erythematous lesions, is a serious condi-
tion accompanying chemotherapy. Efficient localized treatment with mucosal protectors,
keratinizing agents, and local antimicrobials could be achieved by combining a thermore-
versible and mucoadhesive spray hydrogel such as poloxamer–chitosan mixtures. Caricato
et al. developed a spray thermogel for oral delivery of an active natural onion extract. The
onion extract antimicrobial and antioxidant activities, as well as the high biocompatibility
of novel formulation, should be further confirmed in in vivo conditions [347].
Chitosan could be further exploited in different fields of dentistry. From its remineral-
izing property assisting hardening of tooth tissues, improved healing of post extraction
oral wounds, a reduction in bacterial biofilm when applied as dental cements, to widely
explored antibacterial, antifungal, and hemostatic properties. Ciciu et al. provided an
overview of the clinical studies on chitosan-based formulations for dental use [348]. The
role of chitosan in treating various oral health conditions with emphasis on periodontitis
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and endodontic infections has been comprehensively summarized by Fakhri et al. [349].
Periodontitis and dental caries are two of the most prevalent dental bacteria-caused dis-
eases. Their potential link to cardiovascular diseases, diabetes, and central nervous system
disorders, brought focus to the urgent need to treat the infections early and efficiently [342].
P. gingivalis is considered as the primary pathogen causing periodontitis, prone to biofilm
formation [350]. In addition, S. mutans is considered the main causative pathogen for dental
caries [351].
Since our review is focused on the delivery systems, we enlist herewith some of the
interesting delivery systems studied for the improvement of the antimicrobial activity
of chitosan. For example, CNPs reduced the S. mutans adherence up to 93.4% [352].
Covarrubias et al. developed a hybrid copper–chitosan NPs with antibacterial activity
against cariogenic S. mutans and confirmed that chitosan interacts electrostatically with
hydroxyapatite and the bacterial cell wall enhancing the antibiofilm activity of copper–
chitosan NPs [353].
Antibiofilm activity of CNPs against S. mutans, E. faecalis, and C. albicans multi-species
infections was confirmed by Elshinawy and colleagues [354]. The action against E. faecalis
contaminated root canals was also reported by del Carpio-Perochena et al. [355].
Highly relevant is the impact of the chitosan coating of medical devices on reducing the
contamination possibility. Namangkalakul et al. reported that HMW chitosan incorporated
into carboxymethylcellulose is a superior antifungal denture adhesive. Moreover, the
authors suggested that the MW affects the antifungal activity; the LMW chitosan failed to
reduce the fungal load of acrylic resin discs [356]. The issue remains debatable. Various
chitosan-based delivery systems have been evaluated for the treatment of periodontitis,
such as microspheres berrying clindamycin, tetracycline, doxycycline, and chlorhexidine.
For more detailed descriptions, the readers are referred to Fakhri et al. [349]. The same
review summarizes the various chitosan-based NPs, gels, and fibres targeting the same
dental inflammation linked infections.
A more detailed description of the preparation methods applied in the manufac-
turing of novel chitosan-based delivery systems for dental use is offered by Zhang and
co-authors [357].
6.3. Nasal Route
Chitosan has been primarily used in nasal drug delivery as a pharmaceutical excipient,
assuring required bioadhesion of the system. However, its role as antimicrobial needs to
be expanded. For example, excessive use of anti-influenza drugs is believed to contribute
to the emergence of drug-resistant viruses. Therefore, it is important to discover new
treatment approaches [7]. In a pioneering work, Su et al. found that at high concentrations,
the HMW chitosan could inactivate murine norovirus MNV-1 [358]. Li and colleagues
suggested that carbohydrate-functionalized chitosan fibre could be utilized for influenza
virus capture [359]. Zheng and colleagues reported that the innate immune response could
be stimulated by nasal administration of chitosan; the immune response was sufficient to
protect BALB/c mice from infection with the H7N9 virus, a highly relevant and pathogenic
virus [360].
So far, most of the literature on nasal administration of chitosan-based formulations
have focused on vaccine development, as summarized by Boroumand et al. [7].
7. General Considerations
7.1. Toxicity and Irritation
Generally, chitosan is considered nontoxic as well as biocompatible and biodegradable
and already frequently utilized in delivery systems and scaffolds intended for topical
administration [71]. Several products comprising chitosan are already approved by the U.S.
Food and Drug Administration for certain applications [42], such as wound dressings and
sponges with hemostatic properties and could be found on the market [361]. Among the
various chitosan-based marketed products intended for the localized treatment, chitosan
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has been used in hemostatic bandages or gels and sprays for skin wounds in HemCon®
and ChitoClear®, respectively, and as gels and sprays for nasal mucosal membranes in,
e.g., ChitoRhino. A more detailed overview of these chitosan-based products is presented
by Matica et al. [19]. To our knowledge, there are no chitosan-based products intended for
localized treatment of vaginal infections on the market. Nevertheless, chitosan exists in
broad ranges of MWs, DDA and originate from various sources and should therefore be
thoroughly assessed when utilized as a constituent [45]. Moreover, it is pivotal to ensure
that no traces of impurities from these natural products are present in the end-product [361].
Many studies find no or negligible irritancy and adverse effects upon topical, localized
application of chitosan in animal models after, e.g., skin [175,182,187], vaginal [322] or
ocular administration [335,362]. Nevertheless, some studies have found certain negative
effects of chitosan in the in vitro conditions. Wiegand and colleagues fond MW-dependent
cytotoxicity of chitosan in keratinocytes. They reported highly reduced viability in cells
treated with chitosan with MW of around 120 kDa after only two hours, while oligosaccha-
rides caused reduced viability in higher concentrations after 24 h. The cell death seemed
to be mediated by the activation of effector caspases three and seven [363]. Chatelet and
colleagues found that chitosan, independent of DDA, inhibited the proliferation of fibrob-
lasts, while chitosan of lower DDA had antiproliferative effects on keratinocytes. However,
no cytotoxic effects were observed towards any of these cell lines [364]. These studies
highlight the importance of meticulous assessments of the potentially adverse effects of
chitosan. There are many important considerations upon preparing chitosan as delivery
systems or scaffolds in localized therapy; however, most studies seem to deem chitosan
relatively safe.
7.2. Limitations
Chitosan is an attractive and versatile polymer in biomedical applications. The extent
of its applicability reflects in the extensive literature on chitosan-based delivery systems in
pharmaceutical science. Nevertheless, compared to the multitude of research performed,
limited chitosan products are commercially available; moreover, several challenges remain
to be addressed regarding the clinical success of chitosan [5,75,361]. The naturally derived
polymer is generally obtained by deacetylation of chitin from crustacean shells, and the
animal origin entails bacterial and protein contamination [361]. The deacetylation of chitin
will partly remove the contamination; however, not adequately regarding biomedical
application [75]. Moreover, the presence of heavy metals, such as lead, and mercury
limits the purity of chitosan [361]. The production and especially the purification of
chitosan entail a considerable cost that might restrain the development of chitosan products.
However, the lower cost and more basic purification methods for fungal chitosan are
gaining increased interest [20]. Moreover, fungal chitosan is not considered animal-derived
and avoids shellfish allergenic proteins, although, holds fungal-specific antigens. The
attractive diversity of chitosan also introduces challenges; for instance, the varying DDA
and lack of defined MW complicate the passing of regulatory rules [20]. Additionally, the
comparison of performed research is intricate due to variations that can affect chitosan
properties and activity, such as the antimicrobial activity of chitosan [75,365].
The formulation of chitosan-based delivery systems can be limited due to the poor
solubility of chitosan [5]. The solubility of chitosan is dependent on the DDA, MW, and
pH, and chitosan is only soluble under acidic conditions [17]. This limits the possibilities
for application, but it can be advantageous for some routes, such as the vaginal route that
holds a suitable acidic environment [8]. The low pH involves more positively charged
chitosan that intensifies its antimicrobial activity; however, these pH conditions might
harm cells or tissue [75].
Challenges restricting the applicability of chitosan, such as issues of purity, solubility,
pH, stability and mechanical properties, need to be addressed. Moreover, the environmental
impact associated with conventional chitin extraction and processing demands attention
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to assure the sustainability of large-scale chitosan production from an ecological point
of view.
8. Outlook
Chitosan offers numerous advantages as both a pharmaceutical excipient and a mate-
rial with intrinsic antimicrobial potential. We hope that a unique emphasis on its broader
potential as an active building block for various superior formulations destined for lo-
calized antimicrobial therapy will highlight its importance in the current AMR era. Due
to its superiority in bioadhesion and biocompatibility, its use in localized antimicrobial
therapy should be further exploited. It can be tailored to formulate an optimal delivery
system or a device addressing the specific challenges of the administration site such as
the skin and wound infections, a mucosal site such as the vagina, ocular site, nasal, etc.
Its potential in dental formulation needs to be further expanded. Moreover, its ability
to act in synergy, enhancing the antimicrobial potential of active ingredients, requires
more in-depth studies and mechanistic insights. However, it is important to address the
challenges of its sources. The marine sources need to be utilized in an eco-responsible
manner, assuring sustainability. A more green chemistry approach must be used in the
modification of chitosan’s properties. In summary, the extended role of chitosan must be
seen as a dynamic one. The enlisted evidence needs to be further exploited, the somewhat
surprising findings need to be confirmed, and novel roles discovered. In an era of AMR,
the urgency of carrying out these projects should be fairly apparent.
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22. Ardean, C.; Davidescu, C.M.; Nemeş, N.S.; Negrea, A.; Ciopec, M.; Duteanu, N.; Negrea, P.; Duda-Seiman, D.; Muntean, D.
Antimicrobial Activities of Chitosan Derivatives. Pharmaceutics 2021, 13, 1639. [CrossRef]
23. Felipe, V.; Breser, M.L.; Bohl, L.P.; Rodrigues da Silva, E.; Morgante, C.A.; Correa, S.G.; Porporatto, C. Chitosan disrupts biofilm
formation and promotes biofilm eradication in Staphylococcus species isolated from bovine mastitis. Int. J. Biol. Macromol. 2019,
126, 60–67. [CrossRef] [PubMed]
24. Kandimalla, K.K.; Borden, E.; Omtri, R.S.; Boyapati, S.P.; Smith, M.; Lebby, K.; Mulpuru, M.; Gadde, M. Ability of Chitosan Gels
to Disrupt Bacterial Biofilms and Their Applications in the Treatment of Bacterial Vaginosis. J. Pharm. Sci. 2013, 102, 2096–2101.
[CrossRef] [PubMed]
25. Khan, F.; Pham, D.T.N.; Oloketuyi, S.F.; Manivasagan, P.; Oh, J.; Kim, Y.-M. Chitosan and their derivatives: Antibiofilm drugs
against pathogenic bacteria. Colloids Surf. B 2020, 185, 110627. [CrossRef] [PubMed]
26. Alburquenque, C.; Bucarey, S.A.; Neira-Carrillo, A.; Urzúa, B.; Hermosilla, G.; Tapia, C.V. Antifungal activity of low molecular
weight chitosan against clinical isolates of Candida spp. Med. Mycol. 2010, 48, 1018–1023. [CrossRef]
27. Andersen, T.; Mishchenko, E.; Flaten, G.E.; Sollid, J.U.E.; Mattsson, S.; Tho, I.; Škalko-Basnet, N. Chitosan-Based Nanomedicine to
Fight Genital Candida Infections: Chitosomes. Mar. Drugs 2017, 15, 64. [CrossRef]
28. Gomes Neto, R.J.; Genevro, G.M.; de Almeida Paulo, A.; Lopes, P.S.; de Moraes, M.A.; Beppu, M.M. Characterization and in vitro
evaluation of chitosan/konjac glucomannan bilayer film as a wound dressing. Carbohydr. Polym. 2019, 212, 59–66. [CrossRef]
29. Chang, S.-H.; Lin, Y.-Y.; Wu, G.-J.; Huang, C.-H.; Tsai, G.J. Effect of chitosan molecular weight on anti-inflammatory activity in
the RAW 264.7 macrophage model. Int. J. Biol. Macromol. 2019, 131, 167–175. [CrossRef]
30. Friedman, A.J.; Phan, J.; Schairer, D.O.; Champer, J.; Qin, M.; Pirouz, A.; Blecher-Paz, K.; Oren, A.; Liu, P.T.; Modlin, R.L.; et al.
Antimicrobial and Anti-Inflammatory Activity of Chitosan–Alginate Nanoparticles: A Targeted Therapy for Cutaneous Pathogens.
J. Investig. Dermatol. 2013, 133, 1231–1239. [CrossRef]
31. Yoon, H.J.; Moon, M.E.; Park, H.S.; Im, S.Y.; Kim, Y.H. Chitosan oligosaccharide (COS) inhibits LPS-induced inflammatory effects
in RAW 264.7 macrophage cells. Biochem. Biophys. Res. Commun. 2007, 358, 954–959. [CrossRef] [PubMed]
32. Avelelas, F.; Horta, A.; Pinto, L.F.V.; Cotrim Marques, S.; Marques Nunes, P.; Pedrosa, R.; Leandro, S.M. Antifungal and
Antioxidant Properties of Chitosan Polymers Obtained from Nontraditional Polybius henslowii Sources. Mar. Drugs 2019, 17, 239.
[CrossRef]
33. Yen, M.-T.; Yang, J.-H.; Mau, J.-L. Antioxidant properties of chitosan from crab shells. Carbohydr. Polym. 2008, 74, 840–844.
[CrossRef]
34. Hu, Z.; Zhang, D.-Y.; Lu, S.-T.; Li, P.-W.; Li, S.-D. Chitosan-Based Composite Materials for Prospective Hemostatic Applications.
Mar. Drugs 2018, 16, 273. [CrossRef]
35. Ishihara, M.; Nakanishi, K.; Ono, K.; Sato, M.; Kikuchi, M.; Saito, Y.; Yura, H.; Matsui, T.; Hattori, H.; Uenoyama, M.; et al.
Photocrosslinkable chitosan as a dressing for wound occlusion and accelerator in healing process. Biomaterials 2002, 23, 833–840.
[CrossRef]
36. Anjum, S.; Arora, A.; Alam, M.S.; Gupta, B. Development of antimicrobial and scar preventive chitosan hydrogel wound dressings.
Int. J. Pharm. 2016, 508, 92–101. [CrossRef]
37. Minagawa, T.; Okamura, Y.; Shigemasa, Y.; Minami, S.; Okamoto, Y. Effects of molecular weight and deacetylation degree of
chitin/chitosan on wound healing. Carbohydr. Polym. 2007, 67, 640–644. [CrossRef]
Mar. Drugs 2021, 19, 697 41 of 53
38. Moura, L.I.F.; Dias, A.M.A.; Leal, E.C.; Carvalho, L.; de Sousa, H.C.; Carvalho, E. Chitosan-based dressings loaded with
neurotensin—An efficient strategy to improve early diabetic wound healing. Acta Biomater. 2014, 10, 843–857. [CrossRef]
39. Argenziano, M.; Bressan, B.; Luganini, A.; Finesso, N.; Genova, T.; Troia, A.; Giribaldi, G.; Banche, G.; Mandras, N.;
Cuffini, A.M.; et al. Comparative Evaluation of Different Chitosan Species and Derivatives as Candidate Biomaterials for
Oxygen-Loaded Nanodroplet Formulations to Treat Chronic Wounds. Mar. Drugs 2021, 19, 112. [CrossRef] [PubMed]
40. Hemmingsen, L.M.; Julin, K.; Ahsan, L.; Basnet, P.; Johannessen, M.; Škalko-Basnet, N. Chitosomes-In-Chitosan Hydrogel for
Acute Skin Injuries: Prevention and Infection Control. Mar. Drugs 2021, 19, 269. [CrossRef] [PubMed]
41. Ishihara, M.; Obara, K.; Ishizuka, T.; Fujita, M.; Sato, M.; Masuoka, K.; Saito, Y.; Yura, H.; Matsui, T.; Hattori, H.; et al. Controlled
release of fibroblast growth factors and heparin from photocrosslinked chitosan hydrogels and subsequent effect on in vivo
vascularization. J. Biomed. Mater. Res. A 2003, 64A, 551–559. [CrossRef]
42. Bellich, B.; D’Agostino, I.; Semeraro, S.; Gamini, A.; Cesàro, A. “The Good, the Bad and the Ugly” of Chitosans. Mar. Drugs 2016,
14, 99. [CrossRef]
43. Hurler, J.; Škalko-Basnet, N. Potentials of chitosan-based delivery systems in wound therapy: Bioadhesion study. J. Funct.
Biomater. 2012, 3, 37–48. [CrossRef]
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340. Potaś, J.; Szymańska, E.; Wróblewska, M.; Kurowska, I.; Maciejczyk, M.; Basa, A.; Wolska, E.; Wilczewska, A.Z.; Winnicka, K. Mul-
tilayer Films Based on Chitosan/Pectin Polyelectrolyte Complexes as Novel Platforms for Buccal Administration of Clotrimazole.
Pharmaceutics 2021, 13, 1588. [CrossRef] [PubMed]
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